US20070244407A1 - Evoked Response to Stimulation - Google Patents

Evoked Response to Stimulation Download PDF

Info

Publication number
US20070244407A1
US20070244407A1 US11/624,590 US62459007A US2007244407A1 US 20070244407 A1 US20070244407 A1 US 20070244407A1 US 62459007 A US62459007 A US 62459007A US 2007244407 A1 US2007244407 A1 US 2007244407A1
Authority
US
United States
Prior art keywords
electrode
stimulation
evoked response
electrodes
location
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/624,590
Inventor
Ivan Osorio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Inc
Original Assignee
Medtronic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic Inc filed Critical Medtronic Inc
Priority to US11/624,590 priority Critical patent/US20070244407A1/en
Assigned to MEDTRONIC, INC. reassignment MEDTRONIC, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: OSORIO, IVAN
Publication of US20070244407A1 publication Critical patent/US20070244407A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/40Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4094Diagnosing or monitoring seizure diseases, e.g. epilepsy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36082Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/361Phantom sensations, e.g. tinnitus
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/70ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/0002Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • A61B5/0004Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by the type of physiological signal transmitted
    • A61B5/0006ECG or EEG signals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/24Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316Modalities, i.e. specific diagnostic methods
    • A61B5/369Electroencephalography [EEG]

Definitions

  • the invention relates to the evaluation, warning and treatment of neurological disorders such as epilepsy, devices for such evaluation, warning and treatment, including external and implantable devices and systems, and methods and techniques by which the devices and systems operate, and the methods by which patients suffering disorders such as epilepsy are evaluated, warned, and treated by electrical stimulation or some other modality.
  • the invention discloses a probabilistic approach for issuing warnings and/or triggering therapy delivery without relying on conventional event detection or prediction approaches. This may result in therapy delivery before the onset of a neurological event, such as seizure, or even before the onset of a pre-event state, thus preventing the neurological event from occurring.
  • seizure therapies whether pharmacological or electrical, is to treat seizures through an “open-loop” approach.
  • drugs these are dosed based on their half-life and therapeutic ratio, so as to maintain relatively constant drug serum concentrations round-the-clock and avoid large fluctuations (drops or rises in concentrations), that may leave the subject relatively unprotected (if low) or may cause dose-related side effects (if high).
  • electrical stimulation such as with the Neurocybernetic prosthesis (Cyberonics, Houston, Tex.), currents are delivered periodically, round-the-clock.
  • the dosing/stimulation schedule (not the dose or electrical current intensity) of approved therapies does not take into account the actual frequency of seizures or their temporal (e.g., circadian) distributions:
  • the approach is fundamentally the same for a subject with multiple daily seizures or for one with only one every few years, or if the seizures occur only at night or at any time during the daylight. Adjustments in treatment, if any, are made at certain time intervals based on the number of seizures reported by the subject (by seizure diary) or on the frequency and type of side effects over that interval.
  • seizure detection-based closed-loop control known devices attempt to detect the occurrence of a seizure through analysis of biological signals and respond with electrical stimulation or other therapy.
  • seizure prediction-based closed-loop control known devices attempts to detect the occurrence of a pre-seizure state, again through some analysis of biological signals, and respond with delivery of some contingent therapy.
  • a first electrode may be implanted in a patient's brain in a first hemisphere. By applying stimulation pulses to the first electrode, a first evoked response may be measured. The first evoked response may be compared to previous or subsequent evoked responses to determine the part of the brain that is being stimulated by the first electrode.
  • a second electrode may be implanted in a second hemisphere of the patient's brain and evoked responses from the second electrode may be measured. The evoked response from the second electrode may be compared with the response evoked by stimulation of the first electrode to verify that the first and second electrodes are stimulating the same part of the brain, just in different hemispheres. In an embodiment this may be done inter-operatively (e.g., during the electrode implanting process).
  • a closed-loop detection algorithm may be used to determine stimulation parameters that reduce the probability of a neurological disorder such as a seizure.
  • An implantable medical device may be implanted and used to provide electrical stimulation in accordance with the parameters to the first and second electrodes in an open-loop manner.
  • the stimulation may be in a monopolar configuration with the first and second electrodes being used as cathodes while a case of the implantable medical device is used an anode.
  • FIG. 1 is a schematic view of a medical device implanted in a patient that monitors cardiac and nervous system disorders in accordance with an aspect of the invention.
  • FIG. 2 is a simplified block diagram of the medical device shown in FIG. 1 in accordance with an aspect of the invention.
  • FIG. 3 is a graphical representation of various signals sensed by the medical device as shown in FIG. 1 in accordance with an aspect of the invention.
  • FIG. 4 shows an apparatus that supports reporting neurological data in accordance with an aspect of the invention.
  • FIG. 5 is a schematic diagram of a system utilizing the above-described embodiments and allowing remote monitoring and diagnostic evaluation of at risk patients in accordance with an aspect of the invention.
  • FIG. 6 is a schematic diagram of an alternative system utilizing the above-described embodiments and allowing remote monitoring and diagnostic evaluation of at risk patients in accordance with an aspect of the invention.
  • FIG. 7 is a chart of seizure frequency as a function of time of day in some subjects.
  • FIG. 8 is a chart of simulated probability of seizure as a function of time of day, for a supposed patient.
  • FIG. 9 is a chart of probability of seizures as a function of time during a stimulation cycle in some subjects.
  • FIG. 10 is a chart of probability of seizures as a function of time from onset of stimulation in some subjects.
  • FIG. 11 is a chart of probability of seizures as a function of time from beginning of seizure in some subjects.
  • FIG. 12 is a chart of probability of seizures as a function of time relative to therapy delivery in some subjects.
  • FIG. 13 illustrates a process of determining the location of an electrode using an evoked response in accordance with an aspect of the invention.
  • FIG. 14 illustrates a process of applying stimulation to an electrode in accordance with an aspect of the invention.
  • probabilistic approaches that are not based on a strict binary approach for discrete event detection (i.e., “0” for no detection and “1” for detection), or prediction (i.e., “0” for no issuance of prediction and “1” for issuance of a prediction). Instead, disclosed are techniques that estimate probability distribution functions or cumulative distribution functions, “built” relying on representative historical profiles, comprising information in short and/or long timescales obtained at times that may be intermittent or temporally discontinuous from each other or from other events of interest.
  • probabilistic control of seizures is based on the following observations: (1) the probability of seizure occurrence is not solely a function of signal changes in the system but of multiple factors; (2) seizure probability changes as a function of state, being lowest in the period immediately following the termination of seizures; and (3) the anti-seizure effects of closed-loop electrical stimulation, either local (delivered directly to epileptogenic tissue) or remote (delivered to epileptogenic tissue via a structure connected to it), of epileptogenic tissue are both closely temporally correlated with delivery of currents (immediate effect) and persist for some time beyond cessation of stimulation (“carry-over” effect) [Osorio et al 05, Annals of Neurology].
  • stimulation parameters may be adjusted to attain a state of protection that minimizes seizure occurrence probability and whose level or degree of protection is a function of this probability.
  • This strategy referred to as probabilistic closed-loop, may be in certain cases, preferable to conventional closed-loop treatment, which operates only in response to event detections (either seizure detections or, in the case of “prediction,” the detection of a pre-seizure state) and provides event detection-contingent therapy.
  • event detections either seizure detections or, in the case of “prediction,” the detection of a pre-seizure state
  • contingent therapy such as stimulation may be used to treat breakthrough seizures.
  • the “probabilistic closed-loop” may evolve, under certain circumstances and in certain cases, into “intelligent” open-loop defined as lacking immediate or real-time information/“feedback”, but operating according to changes in estimates of seizure probability (as a function of time and/or state) which were calculated using past information and which may be updated/improved (as a function of time and/or state) but not in real-time, using new information.
  • “Intelligent” open-loop does not require that implantable monitoring devices be used for real-time signal processing/analysis for the detection/prediction/quantification of seizures nor that in-hospital monitoring be performed. Instead, portable monitoring devices for ambulatory/home monitoring may be used.
  • the monitoring devices may obtain signals such as EEG, ECoG, EKG or others, preferably via telemetry and periods of intensive monitoring and parameter optimization (with or without closed-loop therapy) may be carried out as often as indicated.
  • signals such as EEG, ECoG, EKG or others
  • telemetry and periods of intensive monitoring and parameter optimization may be carried out as often as indicated.
  • open-loop control is generally therapy that is administered according to a program that depends on time, without taking into account real-time information about the state of the subject.
  • “Closed-loop” is generally refers to the administration of therapy that is dependent upon information about the state of the subject and therapy is triggered if and when seizures are either detected or predicted.
  • intelligent open-loop is generally the triggering of interventions dictated by changes in probability of seizure occurrence estimated using past information. For example, if the mean or median half-life duration of the protective carry-over effect of electrical stimulation in a given patient lasts 20 minutes, as determined with closed-loop or probabilistic closed-loop modalities, electrical stimulation will be delivered again 20 min after each trial, round-the clock. This modality does not use real-time but past information.
  • “probabilistic closed-loop” does not require detection or prediction of seizures for triggering an intervention/therapy delivery, but rather, probabilities that are associated with: (a) an unacceptable value (for the subject or for the situation, etc.) related to safety, social or other risks; (b) a change in value which is rapid and/or large in magnitude for that subject, brain/systems state, time of day or activity; (c) weakening of the “steady-state” of protection (loss of a “carry-over” effect) afforded by previous therapy delivery or inability to attain the sufficient degree of “carry-over” protection following therapy delivery.
  • the invention may be implemented within an implantable neurostimulator system, however, those skilled in the art will appreciate that the techniques disclosed herein may be implemented generally within any implantable medical device system including, but not limited to, implantable drug delivery systems, and implantable systems providing stimulation and drug delivery.
  • the implantable medical device may provide therapeutic treatment to neural tissue in any number of locations in the body including, for example, the brain (which includes the brain stem), the vagus nerve, the spinal cord, peripheral nerves, etc.
  • the treatment therapies can include any number of possible modalities alone or in combination including, for example, electrical stimulation, magnetic stimulation, drug infusion, brain temperature control, and/or any combination thereof.
  • aspects of the invention may be embodied in various forms to analyze and treat nervous system and other disorders, namely disorders of the central nervous system, peripheral nervous system, and mental health and psychiatric disorders.
  • disorders include, for example without limitation, epilepsy, Sudden Unexpected Death in Epilepsy Patients (SUDEP), Parkinson's disease, essential tremor, dystonia, multiple sclerosis (MS), anxiety (such as general anxiety, panic, phobias, post traumatic stress disorder (PTSD), and obsessive compulsive disorder (OCD)), mood disorders (such as major depression, bipolar depression, and dysthymic disorder), sleep disorders (narcolepsy), obesity, tinnitus, stroke, traumatic brain injury, Alzheimer's, and anorexia.
  • SEP Sudden Unexpected Death in Epilepsy Patients
  • Parkinson's disease essential tremor
  • dystonia multiple sclerosis
  • MS multiple sclerosis
  • anxiety such as general anxiety, panic, phobias, post traumatic stress disorder (PTSD), and obsess
  • the biological signals that may selected, stored and/or reported in accordance with various aspects of the invention may include any number of sensed signals.
  • Such biological signals can include, for example, electrical signals (such as EEG, ECoG and/or EKG), chemical signals (such as change in quantity of neurotransmitters), temperature signals, pressure signals (such as blood pressure, intracranial pressure or cardiac pressure), respiration signals, heart rate signals, pH-level signals, activity signals (e.g., detected by an accelerometer), and/or peripheral nerve signals (cuff electrodes on a peripheral nerve).
  • Such biological signals may be recorded using one or more monitoring elements such as monitoring electrodes or sensors.
  • 6,227,203 provides examples of various types of sensors that may be used to detect a symptom or a condition or a nervous system disorder and responsively generate a neurological signal.
  • various types of physiologic activities may be sensed including, for example, brain, heart and/or respiration.
  • the techniques disclosed herein are suitable for use within any implantable medical device system that receives signals associated with the physiological conditions being sensed, a memory component, and a processing component (logic or software) that stores data records in data structures. Certain techniques are also suitable for implantable medical devices with even lesser functionality. For example, in an embodiment where the implantable unit applies open-loop electrical stimulation in a desired pattern, the implantable device may include only those elements necessary to provide the pattern of electrical stimulation. However, an implantable medical device with greater functionality may also be used to provide open-loop stimulation as well as one or more of the additional features discussed herein.
  • Manual indication of a seizure or other event may be achieved through an external programmer device.
  • the patient (or caregiver) may push a button on the external programmer device, while communicating with the implanted device. This may provide a marker of the sensed data (for example, in the event the patient is experiencing a neurological event).
  • ECG recordings may be possible (e.g., recording all data during sleep since the incidence of SUDEP is highest in patients during sleep).
  • Post-processing of the signal can occur in the implanted device, the patient's external device, a clinician external device, and/or another computing device.
  • a patient may download data from the implantable device to the patient external device (as will be discussed further herein), which may then be analyzed by the external device (and/or sent through a network to the physician) to assess any ECG abnormalities. If an abnormality is detected, the device may notify the patient/caregiver.
  • the patient/caregiver may inform the healthcare provider of the alert to allow a full assessment of the abnormality.
  • the clinician external device may also be capable of obtaining the data from the implanted device and conducting an analysis of the stored signals. If a potentially life-threatening abnormality is detected, the appropriate medical treatment may be prescribed (e.g., cardiac abnormality: a pacemaker, an implantable defibrillator, or a heart resynchronization device may be indicated or respiration abnormality: CPAP, patient positioning, or stimulation of respiration may be indicated).
  • cardiac abnormality a pacemaker, an implantable defibrillator, or a heart resynchronization device may be indicated or respiration abnormality: CPAP, patient positioning, or stimulation of respiration may be indicated.
  • the implantable medical device may also monitor EEG signals from intracranially implanted leads. This may allow the implanted medical device to collect cardiovascular and neurological signals in close proximity to detected neurological events as well as notify the patient/caregiver of a prolonged event (and/or status epilepticus). The implantable medical device may detect neurological events and analyze the peri-ictal signals and initiate loop recording.
  • cardiac lead(s), a sensor stub, and/or a wearable patch may be used to facilitate detection of a neurological event and the recording of data and signals pre and post event.
  • An integrated electrode may also be used that senses ECG signals as described in U.S. Pat. No. 5,987,352.
  • the implantable medical device may warn/alert the patient 12 via buzzes, tones, beeps or spoken voice (as substantially described in U.S. Pat. No. 6,067,473) via a piezo-electric transducer incorporated into the housing of implantable medical device. The sound may be transmitted to the patient's inner ear.
  • the monitor may be implanted cranially in the patient 12 ( FIG. 1 ).
  • the monitor may be constructed as substantially described in U.S. Pat. Nos. 5,782,891 and 6,427,086.
  • EEG sensing may be accomplished by the use of integrated electrodes in the housing of the monitor, cranially implanted leads, and or leadless EEG sensing.
  • FIG. 1 illustrates an implantable system 10 including an implantable medical device 20 implanted in a patient 12 .
  • the implantable medical device 100 may monitor one or more biological signals/conditions of the patient via lead 19 and monitoring/sensing elements 30 and 32 (in the embodiment, the biological conditions are cardiac and neurological functions of patient 12 ).
  • Stored diagnostic data may be uplinked and evaluated by an external computing device 23 (e.g., a patient's or physician's programmer) via a 2-way telemetry, using for example, antenna 24 to relay radio frequency signals 22 , 26 between implantable medical device 100 and external computing device 23 .
  • An external patient activator that may be located on external computing device 23 may optionally allow patient 12 , or care provider (not shown), to manually activate the recording of diagnostic data.
  • FIG. 2 depicts a block diagram of the electronic circuitry of implantable medical device 100 of FIG. 1 in accordance with an embodiment of the invention.
  • Implantable medical device 100 comprises a primary control circuit 220 and may be similar in design to that disclosed in U.S. Pat. No. 5,052,388.
  • Primary control circuit 220 includes sense amplifier circuitry 224 , a crystal clock 228 , a random-access memory and read-only memory (RAM/ROM) unit 230 , a central processing unit (CPU) 232 , digital logic circuit 238 , a telemetry circuit 234 , and stimulation engine circuitry 236 , all of which are generally known in the art.
  • Implantable medical device 100 may include internal telemetry circuit 234 so that it is capable of being programmed by means of external programmer/control unit 23 via a 2-way telemetry link.
  • External programmer/control unit 23 communicates via telemetry with implantable medical device 100 so that the programmer can transmit control commands and operational parameter values to be received by the implanted device, and so that the implanted device can communicate diagnostic and operational data to the programmer 23 .
  • programmer 23 may be Models 9790 and CareLink® programmers, commercially available from Medtronic, Inc., Minneapolis, Minn.
  • Various telemetry systems for providing the necessary communications channels between an external programming unit and an implanted device have been developed and are well known in the art. Suitable telemetry systems are disclosed, for example, in U.S. Pat. Nos. 5,127,404; 4,374,382; and 4,556,063.
  • telemetry systems such as those described in the above referenced patents are employed in conjunction with an external programming/processing unit.
  • telemetry systems for implantable medical devices employ a radio-frequency (RF) transmitter and receiver in the device, and a corresponding RF transmitter and receiver in the external programming unit.
  • the transmitter and receiver utilize a wire coil as an antenna 24 for receiving downlink telemetry signals and for radiating RF signals for uplink telemetry.
  • the system is modeled as an air-core coupled transformer.
  • An example of such a telemetry system is shown in U.S. Pat. No. 4,556,063.
  • a digital encoding scheme such as is described in U.S. Pat. No. 5,127,404 can be used.
  • a pulse interval modulation scheme may be employed for downlink telemetry, wherein the external programmer transmits a series of short RF “bursts” or pulses in which the interval between successive pulses (e.g., the interval from the trailing edge of one pulse to the trailing edge of the next) is modulated according to the data to be transmitted.
  • a pulse position modulation scheme may be employed to encode uplink telemetry data.
  • a plurality of time slots are defined in a data frame, and the presence or absence of pulses transmitted during each time slot encodes the data.
  • a sixteen-position data frame may be defined, wherein a pulse in one of the time slots represents a unique four-bit portion of data.
  • Programming units such as the above-referenced Medtronic Models 9790 and CareLink® programmers typically interface with the implanted device through the use of a programming head or programming paddle, a handheld unit adapted to be placed on the patient's body over the implant site of the patient's implanted device.
  • a magnet in the programming head effects reed switch closure in the implanted device to initiate a telemetry session. Thereafter, uplink and downlink communication takes place between the implanted device's transmitter and receiver and a receiver and transmitter disposed within the programming head.
  • primary control circuit 220 includes central processing unit 232 which may be an off-the-shelf programmable microprocessor or microcontroller, but in an embodiment of the invention it may be a custom integrated circuit. Although specific connections between CPU 232 and other components of primary control circuit 220 are not shown in FIG. 2 , it will be apparent to those of ordinary skill in the art that CPU 232 functions to control the timed operation of sense amplifier circuit 224 under control of programming stored in RAM/ROM unit 230 . In addition to or as an alternative embodiment digital logic 238 may also be provided and utilized. In another alternative embodiment, a processing module that contains either a processor or digital circuitry may also be utilized. Those of ordinary skill in the art will be familiar with such an operative arrangement.
  • crystal oscillator circuit 228 provides main timing clock signals to primary control circuit 220 .
  • the various components of implantable medical device 100 are powered by means of a power source such as a battery 239 , which is contained within the hermetic enclosure of implantable medical device 100 .
  • a power source such as a battery 239
  • Sense amplifier 224 is coupled to monitoring/sensing elements 30 and 32 . Where cardiac intrinsic signals are sensed, they may be sensed by sense amplifier 224 as substantially described in U.S. Pat. No. 6,505,067.
  • CPU 232 or digital logic 238 allows detection of cardiac and neural electrical characteristics and anomalies.
  • CPU 232 or digital logic 238 under control of firmware resident in RAM/ROM 230 , may initiate recording of the appropriate diagnostic information into RAM of RAM/ROM 230 .
  • implantable medical device 100 may sense any number of physiologic conditions of the patient 12 for purposes of detecting, and storing data relating to, any number of the neurological events.
  • various lead(s) may be used to facilitate detection of a neurological event and the recording of data and signals pre and post event.
  • an electrode 32 located distally on a sensor stub may be used to facilitate detection of a neurological event and the recording of data and signals pre and post event. See U.S. Pat. No. 5,987,352.
  • the implantable medical device 100 may also sense respiration parameters such as respiration rate, minute ventilation and apnea via measuring and analyzing the impedance variations measured from the implanted implantable medical device 100 case to the electrode located distally on the sensor stub lead as substantially described in U.S. Pat. Nos. 4,567,892 and 4,596,251.
  • an external wearable device such as a wearable patch, a wristwatch, or a wearable computing device may be used to continuously sense implantable medical device cardiac functions of patient 12 .
  • a button (not shown) on the external wearable device may be activated by the patient 12 (or a caregiver) to manually activate data recording (for example, in the event the patient is experiencing a neurological event).
  • the external wearable device may comprise an amplifier, memory, microprocessor, receiver, transmitter and other electronic components as substantially described in U.S. Pat. No. 6,200,265.
  • the device may consist of a resilient substrate affixed to the patient's skin with the use of an adhesive.
  • the substrate flexes in a complimentary manner in response to a patient's body movements providing patient comfort and wearability.
  • the low profile patch is preferably similar in size and shape to a standard bandage, and may be attached to the patient's skin in an inconspicuous location.
  • the disclosed techniques may be implemented within any number of medical device systems (drug delivery, electrical stimulation, pacemaking, defibrillating, cochlear implant, and/or diagnostic).
  • the implanted medical component may utilize one or more monitoring elements (e.g., electrodes or other sensors), a memory component having a plurality of data structures (and/or data structure types), a processing component (such as a CPU or digital logic), and a telemetry component.
  • FIG. 4 shows apparatus 1200 that supports reporting physiological data in accordance with an aspect of the invention.
  • the implanted component 1205 of the medical device system communicates with the relaying module 1215 via telemetry antenna 1210 .
  • the external component 1225 communicates with the relaying module 1215 via antenna 1220 .
  • a telemetry link 1221 between relaying module 1215 and antenna 1220 comprises a 3 MHz body wave telemetry link.
  • the relaying module 1215 may communicate with the external and implanted components using differing communication schemes.
  • the reverse direction and the forward direction of telemetry link 1221 may be associated with different frequency spectra.
  • the relaying module 1215 thereby provides a greater range of communications between components of medical device system.
  • an external programmer may communicate with an implanted device from a more remote location.
  • the external programmer may be across the room and still be in communication via the relaying module 1215 .
  • the use of an implanted system is more convenient to the patient, in particular at night while sleeping or when taking a shower, eliminating the need for an external device to be worn on the body.
  • the system allows the residential, hospital or ambulatory monitoring of at-risk patients and their implanted medical devices at any time and anywhere in the world.
  • Medical support staff 1306 at a remote medical support center 1314 may interrogate and read telemetry from the implanted medical device and reprogram its operation while the patient 12 is at very remote or even unknown locations anywhere in the world.
  • Two-way voice communications 1310 via satellite 1304 , via cellular link 1332 or land lines 1356 with the patient 12 and data/programming communications with the implanted medical device 1358 via a belt worn transponder 1360 may be initiated by the patient 12 or the medical support staff 1306 .
  • the location of the patient 12 and the implanted medical device 1358 may be determined via GPS 1302 and link 1308 and communicated to the medical support network in an emergency. Emergency response teams can be dispatched to the determined patient location with the necessary information to prepare for treatment and provide support after arrival on the scene. See, e.g., U.S. Pat. No. 5,752,976.
  • FIG. 6 An alternative or addition to the system as described above in conjunction with FIG. 5 is shown in the system 1450 of FIG. 6 , which shows a patient 12 sleeping with an implantable Monitor 1458 and/or optional therapy device as described above in connection with the above-described systems.
  • the implantable device 1458 upon detection of a neurological event may alert a remote monitoring location via local remote box 1452 (as described in U.S. Pat. No. 5,752,976), telephone 1454 and phone lines 1456 or the patient's care provider via an RF link 1432 to a pager-sized remote monitor 1460 placed in other locations in the house or carried (i.e., belt worn) by the care provider 1462 .
  • the remote caregiver monitor 1460 may include audible buzzes/tones/beeps, vocal, light and/or vibration to alert the caregiver 1462 of patient's monitor in an alarm/alert condition.
  • the RF link may include RF portable phone frequencies, power line RF links, HomeRF, Bluetooth, ZigBee, WIFI, MICS band (medical implant communications service), or any other interconnect methods as appropriate.
  • Example means include but are not limited to:
  • t time elapsed since beginning of delivery of a particular therapy program.
  • t REL t (mod max ⁇ t i
  • t i ⁇ t ⁇ ).
  • t REL corresponds to the time elapsed since the most recent fiducial time. Examples:
  • the inventors have developed a framework that does not rely on conventional on-line, real-time seizure detection or prediction but utilizes available information (history) to issue warnings and/or deliver therapy based on this developed probability function (as opposed to specific, binary, event detections).
  • This probability function and related decisions of whether or not to issue a warning or deliver therapy can incorporate useful dependency of factors such as type of present activity and its inherent risk of injury, social embarrassment, and importance to preserve cognitive functions.
  • This empirical probability function can be used to compare one therapy control program against another (or against the untreated subject) in order to determine which is more effective and enables adjustment of therapy to improve efficacy.
  • the probability of seizure occurrence is known to change as a function of time of day (from Osorio I, Frei M G, Manly B F J, Sunderam S, Bhavaraju N C, and Wilkinson S B. J Clin Neurophysiol. 2001 November; 18(6):533-44).
  • no turnal epilepsy By examining seizure frequency of occurrence as a function of time of day, one can determine the effect of circadian variations on seizures for a particular subject and use this information to better control their seizures as illustrated in the following example.
  • a subject with primarily nocturnal seizures is monitored continuously for one month (or some period of time that yields a representative or useful sample) with no therapy enabled, and then for a second month (or other period), while being treated with an open loop control program that consists of 5 mA of stimulation at 100 Hz for 1 minute every 10 minutes (i.e., on 1 minute, off 9 minutes).
  • an open loop control program that consists of 5 mA of stimulation at 100 Hz for 1 minute every 10 minutes (i.e., on 1 minute, off 9 minutes).
  • the graphs in FIG. 8 illustrate PE( ⁇ ) for months 1 (solid) and 2 (dash-dot), respectively.
  • the therapy program had a seizure-reduction effect during the night, but may have increased seizure frequency during the day.
  • the user may improve the overall efficacy of therapy by developing a new control program that is obtained by combining the approaches to produce a second control program that is equal to the previous one (on 1 minute, off 9 minutes) during the night, but is off completely between 8:30 and 15:30.
  • this revised control can be expected to result in improved therapy for the subject. While one skilled in the art will appreciate that the aforementioned assumptions need not be valid, the information obtained from the method allows the user to quantify the linearity of the response and the size and duration of the carry-over effect and to suitably modify the control program.
  • FIG. 9 depicts observed changes in seizure duration and intensity as a function of time from onset of stimulation (from S. Sunderam et al., Brain Research 918 (2001) 60-66).
  • the times of stimulation are used as fiducial times to examine the effect on seizure longevity and optimize the stimulation parameters.
  • Seizure probability and severity may also be estimated as a function of time of delivery of therapy (such as electrical stimulation) and may depend upon other relevant parameters such as intensity, duration, frequency, stimulation polarity, etc.
  • the treatment program provides for 2.5 s of continuous stimulation to the anterior thalamic nucleus, triggered by every other seizure detection (generated by an automated seizure detection algorithm).
  • the subject continues to have seizures, so the stimulation duration is increased to 30 s of continuous stimulation, administered to the same brain location, again triggered by every other seizure detection.
  • the monitoring data is collected and analyzed as described above with the fiducial times equal to the starting time of each stimulation.
  • the corresponding probabilities of seizure survival, relative to elapsed time from start of stimulation are shown in FIGS. 10 and 11 . In this manner, the system enables the user to determine the duration of stimulation that has optimal effect in terms of seizure reduction (approximately 15 s), beyond which efficacy is not improved further.
  • FIG. 10 depicts a subject where every other seizure is treated by 2.5 s stimulation beginning at seizure onset.
  • the curves show probability of being in seizure as a function of time from beginning of seizure.
  • the upper curve indicates probability for stimulated seizures, and the lower curve represents those seizures that were not stimulated. No significant difference is evident.
  • FIG. 11 depicts a subject where every other seizure is treated by 30 s stimulation beginning at seizure onset.
  • the curves show probability of being in seizure as a function of time from beginning of seizure. The lowest curve indicates probability for stimulated seizures, the middle curve indicates probability for those seizures that were not stimulated, and the highest curve indicates the baseline probability from pre-treatment phase recordings.
  • a subject that is being treated with an open-loop therapy may be equipped with a device for intensive continuous monitoring of biological signals (such as EEG or EKG), which will detect and quantify features of these signals (e.g., epileptiform brain activity or heart rate changes) associated with seizures for a period of time (e.g., 48 hr).
  • the monitored activity will be analyzed with respect to some fiducial time sequence (e.g., times of onset of stimulation delivery, times of changing of stimulation intensity, time of day, etc.) and the empirical probability density of seizures relative to time with respect to the fiducial sequence is generated.
  • FIG. 12 provides an illustration of such information, in which the fiducial times are the times of onset of trains of electrical stimulation delivered for 30 s every 10 minutes. From this analysis it becomes apparent that the open-loop stimulation program provides very little immediate effect, but has a carry-over, protective effect against seizures that lasts for 2.5 minutes beyond the end of stimulation. This implies that the open-loop stimulation program should be altered to provide 30 s of stimulation every 3 minutes. Similar subsequent analysis can be used to determine the potential benefit of additional fine-tuning of the therapy program.
  • the approach illustrated in the above example can be indirectly tested in future open-loop trials, by measuring changes in seizure frequency over pre-specified time periods as a function of stimulation cycle length (e.g., 1 min ON-5 min OFF vs. 1 min ON-2.5 min OFF); greater reductions in seizure frequency with shorter off cycles than with longer off cycles would demonstrate the direction and benefit of utilizing “carry-over” effect information in seizure prophylaxis or abatement.
  • stimulation cycle length e.g., 1 min ON-5 min OFF vs. 1 min ON-2.5 min OFF
  • greater reductions in seizure frequency with shorter off cycles than with longer off cycles would demonstrate the direction and benefit of utilizing “carry-over” effect information in seizure prophylaxis or abatement.
  • potentially greater benefits may be provided with stimulation applied at relatively high frequencies.
  • Applicants have determined that applying stimulation pulses at frequencies such as 175 Hz to the anterior thalamic nuclei (or neighboring locations) may allow for substantial reductions in seizures in patients that suffer from otherwise inoperable pharmaco-resistant seizures if the stimulation pulses are provided at a rate of one minute stimulation-on, five minutes stimulation-off.
  • High frequency electrical stimulation defined as 100 Hz minimum, may (1) induce synaptic plasticity in the form of short-term depression, long-term depression, or both; (2) upregulate glutamic acid decarboxylase and downregulate calcium-and calmodulin-dependent protein kinase II, the net effect of which is to enhance inhibition at or near the stimulated site.
  • high frequency electrical stimulation increases the seizure threshold in the rat pentylenetetrazol model when delivered to the anterior thalamic nuclei and therefore may have a similar effect in humans.
  • a stimulation signal may be applied with an intensity of 5 volts and an initial round of closed-loop testing may be used to determine the stimulation signal's parameters such as shape, duration, amplitude and any other signal parameter that may be controlled.
  • the intervention delivered by the probabilistic closed-loop methods disclosed herein may be tailored for individual or subject-specific warning and/or treatment based on the frequency and/or severity of seizures, circadian patterns, occupational hazards, social factors, employment demands, etc.
  • the probabilistic closed-loop approach which encompasses the concept of “intelligent open-loop,” may be used to issue “graded” or incremental warnings and/or therapy.
  • the seizure probability in a given patient is estimated to be 40% at a given time.
  • This probability estimate may trigger a warning (vibration or sound) that is half as intense as one associated with a probability twice as high (i.e., 80%).
  • the intensity or type of warning in this embodiment changes as a function of changes in probability, either decreasing or increasing as a function of its value.
  • a warning associated with a certain probability estimate may change as a function of risk of injury or of social embarrassment should a seizure occur; a 40% seizure probability in a patient sitting in a chair at home would be much less intense than if the subject was operating a vehicle.
  • Temperature sensors, accelerometers and/or EKG among other means may be used to determine the level of activity (sedentary vs. in motion) and its relative duration to automatically adjust the level or type of warning. Operation of power equipment or of vehicles may be factored into the warning scale by the patient simply pressing a button prior to initiating these activities.
  • Cars or power equipment may be also equipped with devices that upgrade the warning level as they are turned ON and a disabling device that communicates with the patient's device may be activated should the seizure probability be at an unsafe level.
  • An identical approach may be taken for therapy: The type of therapy and parameters/dose used when the seizure probability is 40% may be different that when it is 80% or when the subject changes activity from a low to a high risk for injury.
  • thalamic stimulation targets may be applied for treatment of the neurological disorder, including particularly mesial temporal and mesial frontal intractable epilepsies.
  • These targets include anterior thalamic nuclei, nucleus Reticulatus polaris, nucleus Latero-polaris, nucleus Antero-medialis, nucleus Ventro-oralis Internus, nucleus Antero-principalis and nucleus Lateropolaris. It is noted that while the anterior thalamic nuclei is a known target for stimulation, success has been experienced when stimulating neighborhood targets.
  • a stimulation target may be a region, which is defined as more than one nucleus or thalamic structure, rather than a single thalamic nucleus or structure.
  • another possible target is the Campus Forelli Pars H2, which is not a direct neighbor of the anterior thalamic nuclei.
  • Other targets are also contemplated and would vary depending on the type of disorder.
  • neighborhood targets may also provide suitable candidates so as to allow the physician implanting the electrode in the target greater latitude in the selection of the target, for certain treatment procedures it is desirable to stimulate the same target in both the right and left hemisphere of the patient's brain. Therefore, the evoked response methodology discussed below provides certain benefits when attempting to implant electrodes in particular regions and/or locations of the brain.
  • evoked responses are generated by applying a stimulation pulse with an implanted target electrode and measuring the resultant response at other electrodes such as scalp electrodes or other depth electrodes.
  • Measurements of amplitude, latency and conduction velocity provide information that allows a determination of the location of the implanted electrode being used to stimulate.
  • the morphology and polarity of the responses provide information about the uniformity of electrode placement intra- and inter-individually since they depend on the nature, location and orientation of the current sources, as well as on volume conduction characteristics which are determined by the electrical and geometric properties of the tissue.
  • This location information also provides information on the connection that the electrode stimulation site has to the desired treatment site, thus indicating whether the stimulation site is a neighboring site of the desired treatment site.
  • evoked responses may be used to assess the precision of lead placement intra- and inter-individually. This complements MRI or other imaging based techniques and is particularly useful for targets that as the ATN, than unlike the STN (for treatment of movement disorders) appear to lack easily identifiable electrophysiological markers. Accurate in-vivo localization of electrodes/contacts and identification of functional or electrographic target markers loom as challenges that must be successfully addressed to identify, with reproducible accuracy in humans, structures with seizure gating capabilities and properly assess the therapeutic value/ratio of open- or closed-loop electrical stimulation.
  • evoked responses techniques as used in a recent investigation do not provide direct information about lead localization, they may be used (a) to indirectly determine if the Epileptogenic Zone(s) and the leads'targets share anatomical connections; and (b) as tools to assess intra- as well as inter-individual uniformity/precision of lead placement.
  • Applicants have determined that the intra- and inter-individual differences in evoked responses in these subjects may accurately predict the probable differences in lead location.
  • the basis for this claim is that the potential or waveform (defined by polarity, morphology and amplitude) at any location in the brain may vary depending on: (1) the nature, location and orientation of the current sources; and (2) volume conduction characteristics which are determined by the electrical and geometric properties of the tissue.
  • Indirect or direct electrical stimulation of brain structures generates reproducible waves or oscillations (i.e., evoked responses), that may be recorded from the scalp (or intra-cerebrally) and have shapes and latencies that are unique for each structure.
  • evoked responses i.e., evoked responses
  • the responses generated by stimulation of structures involved in the processing of sensory signals have characteristic shapes and latencies that are highly similar among different subjects and are easily distinguishable, from those generated by structures involved in processing acoustic stimuli which are also highly similar inter-individually.
  • evoked responses may be used to find out if the structure where the stimulation electrode is being placed has functional connectivity with the remote area whose abnormal activity is being controlled or abated.
  • the presence of reproducible evoked responses in the abnormal or treatment area defined as responses with identical latency, morphology and amplitude obtained from at least 2 separate stimulation trials, is strong evidence that the stimulation area and the abnormal area have functional connectivity.
  • placement of the stimulation electrode may be optimized by monitoring changes in latency, amplitude and morphology in response to small changes in the position (in the x, y or z planes) of the electrode or by changing the part or contact of that electrode through which currents are passed.
  • stimulation parameters are kept constant and a change in the position of the contact and/or a change in the contact provides a decreases in latencies and/or increases in amplitude without changes in overall morphology then the change indicates improved placement.
  • Evoked responses may be also used to find out if a stimulation target has functional connectivity with structures in the opposite hemisphere. This has important practical and clinical applications: If a structure in one hemisphere has functional connectivity with ipsi-lateral and contra-lateral homologous structures, stimulation of one side may suffice, or intermittent stimulation of the two sides may be alternated to provide full time protection. In other words, the total stimulation energy may be reduced because only side is stimulated at a time. This can extend the life of an implantable medical device with a limited power source and can also potentially reduce any negative cognitive effects that the stimulation might have.
  • FIG. 13 illustrates an embodiment of implanting and locating electrodes using evoked responses.
  • an electrode is positioned in a first hemisphere of the patient's brain.
  • the electrode may be shaped to stimulate more than one target site (for example, may be shaped like a shaft) and in another embodiment the electrode may be one of a plurality of electrodes in an array on a lead.
  • a stimulation pulse is applied and the evoked response measured.
  • the evoked response is compared to an evoked response of an electrode positioned in a desired location, either in the current patient or in another patient. If the electrode is not in the desired position, steps 410 and 420 are repeated. It should be noted that in an embodiment where the electrode is one of a plurality of electrodes in an array, some portion of the electrodes may be selected and stimulated and step 420 may be repeated for each contact that is selected. As can be appreciated, in such an embodiment there may be no need to adjust the position of the lead if the first electrode is not properly positioned, rather the position of the selected contact on the lead can be changed until an electrode is determined to be positioned in a desired location. It should be noted that in a situation where a region is the intended target, the location of the first electrode is acceptable as long as the location is within the target region.
  • a second electrode is positioned in a second hemisphere in step 440 .
  • the second electrode may be positioned in the right hemisphere.
  • the a stimulation pulse is applied to the second electrode and in step 460 a check is made to see if the location of the second electrode correspond to the position of the first electrode. If the location of the second electrode is determined to not match the desired location, steps 440 - 460 may be repeated. Therefore, in an embodiment the position of the second electrode can be made to correspond to the position of the first electrode by ensuring the evoked response of the second electrode is substantially identical to the evoked response of the first electrode.
  • the positioning of the second electrode can be simply selecting a different electrode from the array of electrodes.
  • an indication which may be textual or graphical, can be provided on a display so that the person implanting the electrode has a visual feedback on the location of the electrode. Therefore, the depicted process is representative and is not intended to be limiting unless otherwise noted.
  • FIG. 14 illustrates an embodiment of applying open-loop stimulation in accordance with one or more embodiments of the present invention.
  • a plurality of electrodes is implanted at the desired location. It should be noted that precise electrode placement is not an easy task; therefore, a check may be made to determine the location of a plurality of implanted electrodes during the implanting process as discussed above in FIG. 13 . It should be noted that plurality of electrodes may be situated in an array and may be situated on more than one lead.
  • an initial analysis is conducted with the electrodes. This analysis may use the probabilistic algorithms discussed above to determine stimulation parameters for reducing the occurrence of seizures when stimulation is applied at the one or more electrodes. It should be noted that using multiple electrodes has the advantage of potentially being able to stimulate a greater volume of brain tissue and, therefore, the application of a stimulation pulse to two or more electrodes may be desirable for certain types of treatment.
  • an implantable medical device may be implanted in step 530 .
  • the implanted medical device does not need to sense neurological signals and does not have to store events in an on-board memory.
  • the stimulation device may also include recording features so that sensed signals may be analyzed at a later time.
  • the implantable medical device may also be configured to record events, such as seizures, generated by a user actuating a programmer. In such a configuration the implantable medical device may communicate via telemetry in a known manner.
  • the implantable medical device begins to provide stimulation in an open-loop fashion.
  • the stimulation may be bi-phasic at a high frequency such as 175 Hz and the electrodes that are selected may be the cathode ( ⁇ ) and the device case, which may be in the patient's chest, the anode (+) (a “monopolar” type configuration).
  • the stimulation may be at an intensity of 5 volts with a repeating pattern of a period of one minute of stimulation followed by five minutes of no stimulation.
  • step 560 analysis is conducted to determine the efficacy of the treatment program.
  • the implanted medical device detects and stores events such as seizures
  • the information may be downloaded from the implanted device in a known manner and analyzed.
  • this process can be initiated and conducted remotely.
  • the analysis may include a determination of the reduction in seizure frequency and/or severity as well as an evaluation of cognitive and motor-sensory skills to determine a more complete picture of the effects of the treatment.
  • the implantable medical device may be implanted and first used in a closed-loop configuration to determine the desired stimulation parameters and/or the location of the electrodes and then be switched to an open-loop stimulation mode to conserve power.

Abstract

In an embodiment, an evoked response of an electrode may be determined. The evoked response may be compared to other evoked responses to determine the location of the electrode. The evoked response may be measured during electrode implantation so that desired changes can be made and if electrodes are being implanted in both the right and left hemisphere, it can be determined that both electrodes are positioned in the same target in both the right and left hemisphere. The evoked responses may be used to determine if the stimulation target has functional connectivity with the treatment areas. Stimulation parameters for the electrodes may be determined in a closed-loop configuration and used to stimulation the electrodes in an open-loop configuration designed to reduce the probability of neurological events such as seizures.

Description

  • This is a continuation-in-part of U.S. application Ser. No. 11/380,752, filed Apr. 28, 2006 (Attorney Docket No. 011738.00310), which in turn claims priority to U.S. Provisional Application Ser. No. 60/780,954 filed Mar. 10, 2006 (Attorney Docket No. 011738.00294), both of which are incorporated herein by reference in their entirety.
  • BACKGROUND OF THE INVENTION
  • The invention relates to the evaluation, warning and treatment of neurological disorders such as epilepsy, devices for such evaluation, warning and treatment, including external and implantable devices and systems, and methods and techniques by which the devices and systems operate, and the methods by which patients suffering disorders such as epilepsy are evaluated, warned, and treated by electrical stimulation or some other modality. Specifically, the invention discloses a probabilistic approach for issuing warnings and/or triggering therapy delivery without relying on conventional event detection or prediction approaches. This may result in therapy delivery before the onset of a neurological event, such as seizure, or even before the onset of a pre-event state, thus preventing the neurological event from occurring.
  • BRIEF DESCRIPTION OF THE PRIOR ART
  • The objective of currently approved seizure therapies, whether pharmacological or electrical, is to treat seizures through an “open-loop” approach. In the case of drugs, these are dosed based on their half-life and therapeutic ratio, so as to maintain relatively constant drug serum concentrations round-the-clock and avoid large fluctuations (drops or rises in concentrations), that may leave the subject relatively unprotected (if low) or may cause dose-related side effects (if high). In the case of electrical stimulation such as with the Neurocybernetic prosthesis (Cyberonics, Houston, Tex.), currents are delivered periodically, round-the-clock.
  • For drugs and electrical stimulation, the dosing/stimulation schedule (not the dose or electrical current intensity) of approved therapies does not take into account the actual frequency of seizures or their temporal (e.g., circadian) distributions: The approach is fundamentally the same for a subject with multiple daily seizures or for one with only one every few years, or if the seizures occur only at night or at any time during the daylight. Adjustments in treatment, if any, are made at certain time intervals based on the number of seizures reported by the subject (by seizure diary) or on the frequency and type of side effects over that interval.
  • Since the advent of automated means for detecting seizures (see, e.g., U.S. Pat. No. 5,995,868 Osorio et al.; Neuropace; Litt) and of methods that allegedly predict the onset of seizures (see, e.g., patents issued to lasemidis; Litt; Hively, Lenhertz), warning and closed-loop therapeutic intervention in response to the output of those methods is now possible. This approach is potentially highly temporo-spatially selective, minimizing adverse effects and unnecessary treatments and in theory, may be superior to open-loop. However, all known, useful prior-art closed-loop therapies restrict intervention to be contingent upon discrete event detections and require that signals (EEG or other types) be continuously monitored (around the clock and for the life of the subject) to enable these event detections.
  • In the case of seizure detection-based closed-loop control, known devices attempt to detect the occurrence of a seizure through analysis of biological signals and respond with electrical stimulation or other therapy. In the case of seizure prediction-based closed-loop control, known devices attempts to detect the occurrence of a pre-seizure state, again through some analysis of biological signals, and respond with delivery of some contingent therapy.
  • These approaches to closed-loop control remain based on relatively short time scales of changes (seconds to minutes in the case of seizure detection, seconds to a few hours in the case of seizure prediction) and typically are based on the assumption that the detection is connected in a dynamically contiguous way with the ongoing or impending seizure. In addition, these approaches ignore temporal correlations between seizures including long-range dependencies.
  • SUMMARY OF THE INVENTION
  • The following represents a simplified summary of some embodiments of the invention in order to provide a basic understanding of various aspects of the invention. This summary is not an extensive overview of the invention. It is not intended to identify key or critical elements of the invention or to delineate the scope of the invention. Its sole purpose is to present some embodiments of the invention in simplified form as a prelude to the more detailed description that is presented below.
  • In an embodiment, a first electrode may be implanted in a patient's brain in a first hemisphere. By applying stimulation pulses to the first electrode, a first evoked response may be measured. The first evoked response may be compared to previous or subsequent evoked responses to determine the part of the brain that is being stimulated by the first electrode. A second electrode may be implanted in a second hemisphere of the patient's brain and evoked responses from the second electrode may be measured. The evoked response from the second electrode may be compared with the response evoked by stimulation of the first electrode to verify that the first and second electrodes are stimulating the same part of the brain, just in different hemispheres. In an embodiment this may be done inter-operatively (e.g., during the electrode implanting process).
  • In an embodiment, a closed-loop detection algorithm may be used to determine stimulation parameters that reduce the probability of a neurological disorder such as a seizure. An implantable medical device may be implanted and used to provide electrical stimulation in accordance with the parameters to the first and second electrodes in an open-loop manner. In an embodiment, the stimulation may be in a monopolar configuration with the first and second electrodes being used as cathodes while a case of the implantable medical device is used an anode.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The present invention is illustrated by way of example and not limited in the accompanying figures in which like reference numerals indicate similar elements and in which:
  • FIG. 1 is a schematic view of a medical device implanted in a patient that monitors cardiac and nervous system disorders in accordance with an aspect of the invention.
  • FIG. 2 is a simplified block diagram of the medical device shown in FIG. 1 in accordance with an aspect of the invention.
  • FIG. 3 is a graphical representation of various signals sensed by the medical device as shown in FIG. 1 in accordance with an aspect of the invention.
  • FIG. 4 shows an apparatus that supports reporting neurological data in accordance with an aspect of the invention.
  • FIG. 5 is a schematic diagram of a system utilizing the above-described embodiments and allowing remote monitoring and diagnostic evaluation of at risk patients in accordance with an aspect of the invention.
  • FIG. 6 is a schematic diagram of an alternative system utilizing the above-described embodiments and allowing remote monitoring and diagnostic evaluation of at risk patients in accordance with an aspect of the invention.
  • FIG. 7 is a chart of seizure frequency as a function of time of day in some subjects.
  • FIG. 8 is a chart of simulated probability of seizure as a function of time of day, for a supposed patient.
  • FIG. 9 is a chart of probability of seizures as a function of time during a stimulation cycle in some subjects.
  • FIG. 10 is a chart of probability of seizures as a function of time from onset of stimulation in some subjects.
  • FIG. 11 is a chart of probability of seizures as a function of time from beginning of seizure in some subjects.
  • FIG. 12 is a chart of probability of seizures as a function of time relative to therapy delivery in some subjects.
  • FIG. 13 illustrates a process of determining the location of an electrode using an evoked response in accordance with an aspect of the invention.
  • FIG. 14 illustrates a process of applying stimulation to an electrode in accordance with an aspect of the invention.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • Overview
  • The following discloses approaches to patient evaluation, warning and treatment, referred herein to as “probabilistic” approaches, that are not based on a strict binary approach for discrete event detection (i.e., “0” for no detection and “1” for detection), or prediction (i.e., “0” for no issuance of prediction and “1” for issuance of a prediction). Instead, disclosed are techniques that estimate probability distribution functions or cumulative distribution functions, “built” relying on representative historical profiles, comprising information in short and/or long timescales obtained at times that may be intermittent or temporally discontinuous from each other or from other events of interest.
  • Conventional “open-loop” control (i.e., that which is implemented in the absence of immediate information or “feedback”) is comparatively easy to implement, as it does not require that a device monitor in real-time, the state of the subject and decipher the relevant information. Conventional closed-loop control is a more powerful class of therapy than conventional open-loop, and while more expensive/complicated than open-loop, it offers greater opportunity for success in certain cases. Both approaches, closed-loop and open-loop, as currently utilized, have advantages and disadvantages relative to one another. In the embodiments disclose herein are techniques, termed “probabilistic closed-loop,” that provide a new approach to therapy or control that draws on the strengths of the two approaches and attempts to advance beyond what may be perceived as their respective limitations.
  • In the embodiment of treating or controlling seizures, probabilistic control of seizures is based on the following observations: (1) the probability of seizure occurrence is not solely a function of signal changes in the system but of multiple factors; (2) seizure probability changes as a function of state, being lowest in the period immediately following the termination of seizures; and (3) the anti-seizure effects of closed-loop electrical stimulation, either local (delivered directly to epileptogenic tissue) or remote (delivered to epileptogenic tissue via a structure connected to it), of epileptogenic tissue are both closely temporally correlated with delivery of currents (immediate effect) and persist for some time beyond cessation of stimulation (“carry-over” effect) [Osorio et al 05, Annals of Neurology].
  • Depending on the duration and degree of protective “carry-over” effect, stimulation parameters may be adjusted to attain a state of protection that minimizes seizure occurrence probability and whose level or degree of protection is a function of this probability. This strategy, referred to as probabilistic closed-loop, may be in certain cases, preferable to conventional closed-loop treatment, which operates only in response to event detections (either seizure detections or, in the case of “prediction,” the detection of a pre-seizure state) and provides event detection-contingent therapy. Of course, both options may be used together, i.e., one does not necessarily preclude the other. For example, contingent therapy such as stimulation may be used to treat breakthrough seizures. Moreover, if future studies show, as did one study [Osorio 05], that short closed-loop trials help identify efficacious parameters, they may be followed by open-loop phases, making open-loop intelligent or adaptive (“intelligent open-loop”).
  • The “probabilistic closed-loop” may evolve, under certain circumstances and in certain cases, into “intelligent” open-loop defined as lacking immediate or real-time information/“feedback”, but operating according to changes in estimates of seizure probability (as a function of time and/or state) which were calculated using past information and which may be updated/improved (as a function of time and/or state) but not in real-time, using new information. “Intelligent” open-loop does not require that implantable monitoring devices be used for real-time signal processing/analysis for the detection/prediction/quantification of seizures nor that in-hospital monitoring be performed. Instead, portable monitoring devices for ambulatory/home monitoring may be used. The monitoring devices may obtain signals such as EEG, ECoG, EKG or others, preferably via telemetry and periods of intensive monitoring and parameter optimization (with or without closed-loop therapy) may be carried out as often as indicated. By decreasing reliance on continuous signal monitoring, this alternative therapeutic regimen simplifies operation and decreases power requirements, factors that translate into smaller, more efficient and less costly implantable therapy devices.
  • As used herein, “open-loop” control is generally therapy that is administered according to a program that depends on time, without taking into account real-time information about the state of the subject. “Closed-loop” is generally refers to the administration of therapy that is dependent upon information about the state of the subject and therapy is triggered if and when seizures are either detected or predicted.
  • As used herein, “intelligent open-loop” is generally the triggering of interventions dictated by changes in probability of seizure occurrence estimated using past information. For example, if the mean or median half-life duration of the protective carry-over effect of electrical stimulation in a given patient lasts 20 minutes, as determined with closed-loop or probabilistic closed-loop modalities, electrical stimulation will be delivered again 20 min after each trial, round-the clock. This modality does not use real-time but past information.
  • As described herein, “probabilistic closed-loop” does not require detection or prediction of seizures for triggering an intervention/therapy delivery, but rather, probabilities that are associated with: (a) an unacceptable value (for the subject or for the situation, etc.) related to safety, social or other risks; (b) a change in value which is rapid and/or large in magnitude for that subject, brain/systems state, time of day or activity; (c) weakening of the “steady-state” of protection (loss of a “carry-over” effect) afforded by previous therapy delivery or inability to attain the sufficient degree of “carry-over” protection following therapy delivery.
  • Embodiments of the Medical Device System
  • In an embodiment, the invention may be implemented within an implantable neurostimulator system, however, those skilled in the art will appreciate that the techniques disclosed herein may be implemented generally within any implantable medical device system including, but not limited to, implantable drug delivery systems, and implantable systems providing stimulation and drug delivery. The implantable medical device may provide therapeutic treatment to neural tissue in any number of locations in the body including, for example, the brain (which includes the brain stem), the vagus nerve, the spinal cord, peripheral nerves, etc. The treatment therapies can include any number of possible modalities alone or in combination including, for example, electrical stimulation, magnetic stimulation, drug infusion, brain temperature control, and/or any combination thereof.
  • In addition, aspects of the invention may be embodied in various forms to analyze and treat nervous system and other disorders, namely disorders of the central nervous system, peripheral nervous system, and mental health and psychiatric disorders. Such disorders include, for example without limitation, epilepsy, Sudden Unexpected Death in Epilepsy Patients (SUDEP), Parkinson's disease, essential tremor, dystonia, multiple sclerosis (MS), anxiety (such as general anxiety, panic, phobias, post traumatic stress disorder (PTSD), and obsessive compulsive disorder (OCD)), mood disorders (such as major depression, bipolar depression, and dysthymic disorder), sleep disorders (narcolepsy), obesity, tinnitus, stroke, traumatic brain injury, Alzheimer's, and anorexia.
  • In certain embodiment, the biological signals that may selected, stored and/or reported in accordance with various aspects of the invention may include any number of sensed signals. Such biological signals can include, for example, electrical signals (such as EEG, ECoG and/or EKG), chemical signals (such as change in quantity of neurotransmitters), temperature signals, pressure signals (such as blood pressure, intracranial pressure or cardiac pressure), respiration signals, heart rate signals, pH-level signals, activity signals (e.g., detected by an accelerometer), and/or peripheral nerve signals (cuff electrodes on a peripheral nerve). Such biological signals may be recorded using one or more monitoring elements such as monitoring electrodes or sensors. For example, U.S. Pat. No. 6,227,203 provides examples of various types of sensors that may be used to detect a symptom or a condition or a nervous system disorder and responsively generate a neurological signal. In addition, various types of physiologic activities may be sensed including, for example, brain, heart and/or respiration.
  • As discussed, the techniques disclosed herein are suitable for use within any implantable medical device system that receives signals associated with the physiological conditions being sensed, a memory component, and a processing component (logic or software) that stores data records in data structures. Certain techniques are also suitable for implantable medical devices with even lesser functionality. For example, in an embodiment where the implantable unit applies open-loop electrical stimulation in a desired pattern, the implantable device may include only those elements necessary to provide the pattern of electrical stimulation. However, an implantable medical device with greater functionality may also be used to provide open-loop stimulation as well as one or more of the additional features discussed herein.
  • Manual indication of a seizure or other event may be achieved through an external programmer device. The patient (or caregiver) may push a button on the external programmer device, while communicating with the implanted device. This may provide a marker of the sensed data (for example, in the event the patient is experiencing a neurological event).
  • In assessing the risk of SUDEP, for example, prolonged ECG recordings may be possible (e.g., recording all data during sleep since the incidence of SUDEP is highest in patients during sleep). Post-processing of the signal can occur in the implanted device, the patient's external device, a clinician external device, and/or another computing device. Intermittently (e.g., every morning, once/week, following a seizure), a patient may download data from the implantable device to the patient external device (as will be discussed further herein), which may then be analyzed by the external device (and/or sent through a network to the physician) to assess any ECG abnormalities. If an abnormality is detected, the device may notify the patient/caregiver. At that time, the patient/caregiver may inform the healthcare provider of the alert to allow a full assessment of the abnormality. The clinician external device may also be capable of obtaining the data from the implanted device and conducting an analysis of the stored signals. If a potentially life-threatening abnormality is detected, the appropriate medical treatment may be prescribed (e.g., cardiac abnormality: a pacemaker, an implantable defibrillator, or a heart resynchronization device may be indicated or respiration abnormality: CPAP, patient positioning, or stimulation of respiration may be indicated). These data may be used to build probability estimates as a function of time, state (asleep or in seizure) and activities (exercising) to enable therapies at times of high risk to prevent an event or, in the case of SUDEP, a fatal outcome.
  • Moreover, the implantable medical device may also monitor EEG signals from intracranially implanted leads. This may allow the implanted medical device to collect cardiovascular and neurological signals in close proximity to detected neurological events as well as notify the patient/caregiver of a prolonged event (and/or status epilepticus). The implantable medical device may detect neurological events and analyze the peri-ictal signals and initiate loop recording.
  • Again, it will be appreciated that alternative embodiments of the implantable medical device may also be utilized. For example, cardiac lead(s), a sensor stub, and/or a wearable patch may be used to facilitate detection of a neurological event and the recording of data and signals pre and post event. An integrated electrode may also be used that senses ECG signals as described in U.S. Pat. No. 5,987,352. Optionally, the implantable medical device may warn/alert the patient 12 via buzzes, tones, beeps or spoken voice (as substantially described in U.S. Pat. No. 6,067,473) via a piezo-electric transducer incorporated into the housing of implantable medical device. The sound may be transmitted to the patient's inner ear.
  • In another embodiment, the monitor may be implanted cranially in the patient 12 (FIG. 1). In such an embodiment, the monitor may be constructed as substantially described in U.S. Pat. Nos. 5,782,891 and 6,427,086. EEG sensing may be accomplished by the use of integrated electrodes in the housing of the monitor, cranially implanted leads, and or leadless EEG sensing.
  • FIG. 1 illustrates an implantable system 10 including an implantable medical device 20 implanted in a patient 12. Optionally, the implantable medical device 100 may monitor one or more biological signals/conditions of the patient via lead 19 and monitoring/sensing elements 30 and 32 (in the embodiment, the biological conditions are cardiac and neurological functions of patient 12). Stored diagnostic data may be uplinked and evaluated by an external computing device 23 (e.g., a patient's or physician's programmer) via a 2-way telemetry, using for example, antenna 24 to relay radio frequency signals 22, 26 between implantable medical device 100 and external computing device 23. An external patient activator that may be located on external computing device 23 may optionally allow patient 12, or care provider (not shown), to manually activate the recording of diagnostic data.
  • FIG. 2 depicts a block diagram of the electronic circuitry of implantable medical device 100 of FIG. 1 in accordance with an embodiment of the invention. Implantable medical device 100 comprises a primary control circuit 220 and may be similar in design to that disclosed in U.S. Pat. No. 5,052,388. Primary control circuit 220 includes sense amplifier circuitry 224, a crystal clock 228, a random-access memory and read-only memory (RAM/ROM) unit 230, a central processing unit (CPU) 232, digital logic circuit 238, a telemetry circuit 234, and stimulation engine circuitry 236, all of which are generally known in the art.
  • Implantable medical device 100 may include internal telemetry circuit 234 so that it is capable of being programmed by means of external programmer/control unit 23 via a 2-way telemetry link. External programmer/control unit 23 communicates via telemetry with implantable medical device 100 so that the programmer can transmit control commands and operational parameter values to be received by the implanted device, and so that the implanted device can communicate diagnostic and operational data to the programmer 23. For example, programmer 23 may be Models 9790 and CareLink® programmers, commercially available from Medtronic, Inc., Minneapolis, Minn. Various telemetry systems for providing the necessary communications channels between an external programming unit and an implanted device have been developed and are well known in the art. Suitable telemetry systems are disclosed, for example, in U.S. Pat. Nos. 5,127,404; 4,374,382; and 4,556,063.
  • Typically, telemetry systems such as those described in the above referenced patents are employed in conjunction with an external programming/processing unit. Most commonly, telemetry systems for implantable medical devices employ a radio-frequency (RF) transmitter and receiver in the device, and a corresponding RF transmitter and receiver in the external programming unit. Within the implantable device, the transmitter and receiver utilize a wire coil as an antenna 24 for receiving downlink telemetry signals and for radiating RF signals for uplink telemetry. The system is modeled as an air-core coupled transformer. An example of such a telemetry system is shown in U.S. Pat. No. 4,556,063.
  • In order to communicate digital data using RF telemetry, a digital encoding scheme such as is described in U.S. Pat. No. 5,127,404 can be used. In particular, a pulse interval modulation scheme may be employed for downlink telemetry, wherein the external programmer transmits a series of short RF “bursts” or pulses in which the interval between successive pulses (e.g., the interval from the trailing edge of one pulse to the trailing edge of the next) is modulated according to the data to be transmitted. For uplink telemetry, a pulse position modulation scheme may be employed to encode uplink telemetry data. For pulse position modulation, a plurality of time slots are defined in a data frame, and the presence or absence of pulses transmitted during each time slot encodes the data. For example, a sixteen-position data frame may be defined, wherein a pulse in one of the time slots represents a unique four-bit portion of data.
  • Programming units such as the above-referenced Medtronic Models 9790 and CareLink® programmers typically interface with the implanted device through the use of a programming head or programming paddle, a handheld unit adapted to be placed on the patient's body over the implant site of the patient's implanted device. A magnet in the programming head effects reed switch closure in the implanted device to initiate a telemetry session. Thereafter, uplink and downlink communication takes place between the implanted device's transmitter and receiver and a receiver and transmitter disposed within the programming head.
  • As previously noted, primary control circuit 220 includes central processing unit 232 which may be an off-the-shelf programmable microprocessor or microcontroller, but in an embodiment of the invention it may be a custom integrated circuit. Although specific connections between CPU 232 and other components of primary control circuit 220 are not shown in FIG. 2, it will be apparent to those of ordinary skill in the art that CPU 232 functions to control the timed operation of sense amplifier circuit 224 under control of programming stored in RAM/ROM unit 230. In addition to or as an alternative embodiment digital logic 238 may also be provided and utilized. In another alternative embodiment, a processing module that contains either a processor or digital circuitry may also be utilized. Those of ordinary skill in the art will be familiar with such an operative arrangement.
  • With continued reference to FIG. 2, crystal oscillator circuit 228 provides main timing clock signals to primary control circuit 220. The various components of implantable medical device 100 are powered by means of a power source such as a battery 239, which is contained within the hermetic enclosure of implantable medical device 100. For the sake of clarity in the figures, the connections between the battery 239 and the other components of implantable medical device 100 are not shown. Sense amplifier 224 is coupled to monitoring/ sensing elements 30 and 32. Where cardiac intrinsic signals are sensed, they may be sensed by sense amplifier 224 as substantially described in U.S. Pat. No. 6,505,067.
  • Processing by CPU 232 or digital logic 238 allows detection of cardiac and neural electrical characteristics and anomalies. CPU 232 or digital logic 238, under control of firmware resident in RAM/ROM 230, may initiate recording of the appropriate diagnostic information into RAM of RAM/ROM 230.
  • It will be appreciated that alternative embodiments of implantable medical device 100 may also be utilized. As discussed above, implantable medical device 100 may sense any number of physiologic conditions of the patient 12 for purposes of detecting, and storing data relating to, any number of the neurological events. For example, various lead(s) may be used to facilitate detection of a neurological event and the recording of data and signals pre and post event.
  • In another aspect of the invention, an electrode 32 located distally on a sensor stub may be used to facilitate detection of a neurological event and the recording of data and signals pre and post event. See U.S. Pat. No. 5,987,352. In alternative embodiments of the invention, the implantable medical device 100 may also sense respiration parameters such as respiration rate, minute ventilation and apnea via measuring and analyzing the impedance variations measured from the implanted implantable medical device 100 case to the electrode located distally on the sensor stub lead as substantially described in U.S. Pat. Nos. 4,567,892 and 4,596,251.
  • In yet another aspect of the invention, an external wearable device such as a wearable patch, a wristwatch, or a wearable computing device may be used to continuously sense implantable medical device cardiac functions of patient 12. Optionally, a button (not shown) on the external wearable device may be activated by the patient 12 (or a caregiver) to manually activate data recording (for example, in the event the patient is experiencing a neurological event). The external wearable device may comprise an amplifier, memory, microprocessor, receiver, transmitter and other electronic components as substantially described in U.S. Pat. No. 6,200,265. In the embodiment of a wearable patch, the device may consist of a resilient substrate affixed to the patient's skin with the use of an adhesive. The substrate flexes in a complimentary manner in response to a patient's body movements providing patient comfort and wearability. The low profile patch is preferably similar in size and shape to a standard bandage, and may be attached to the patient's skin in an inconspicuous location.
  • The above embodiments illustrate that the disclosed techniques may be implemented within any number of medical device systems (drug delivery, electrical stimulation, pacemaking, defibrillating, cochlear implant, and/or diagnostic). Thus, for example without limitation, the implanted medical component may utilize one or more monitoring elements (e.g., electrodes or other sensors), a memory component having a plurality of data structures (and/or data structure types), a processing component (such as a CPU or digital logic), and a telemetry component.
  • FIG. 4 shows apparatus 1200 that supports reporting physiological data in accordance with an aspect of the invention. With apparatus 1200, the implanted component 1205 of the medical device system communicates with the relaying module 1215 via telemetry antenna 1210. Similarly, the external component 1225 communicates with the relaying module 1215 via antenna 1220. In the embodiment, a telemetry link 1221 between relaying module 1215 and antenna 1220 comprises a 3 MHz body wave telemetry link. To avoid interference, the relaying module 1215 may communicate with the external and implanted components using differing communication schemes. In some embodiments, the reverse direction and the forward direction of telemetry link 1221 may be associated with different frequency spectra. The relaying module 1215 thereby provides a greater range of communications between components of medical device system. For example, in the embodiment of an implanted system, an external programmer may communicate with an implanted device from a more remote location. The external programmer may be across the room and still be in communication via the relaying module 1215. With the telemetry booster stage, the use of an implanted system is more convenient to the patient, in particular at night while sleeping or when taking a shower, eliminating the need for an external device to be worn on the body.
  • As shown in FIG. 5, in an embodiment, the system allows the residential, hospital or ambulatory monitoring of at-risk patients and their implanted medical devices at any time and anywhere in the world. Medical support staff 1306 at a remote medical support center 1314 may interrogate and read telemetry from the implanted medical device and reprogram its operation while the patient 12 is at very remote or even unknown locations anywhere in the world. Two-way voice communications 1310 via satellite 1304, via cellular link 1332 or land lines 1356 with the patient 12 and data/programming communications with the implanted medical device 1358 via a belt worn transponder 1360 may be initiated by the patient 12 or the medical support staff 1306. The location of the patient 12 and the implanted medical device 1358 may be determined via GPS 1302 and link 1308 and communicated to the medical support network in an emergency. Emergency response teams can be dispatched to the determined patient location with the necessary information to prepare for treatment and provide support after arrival on the scene. See, e.g., U.S. Pat. No. 5,752,976.
  • An alternative or addition to the system as described above in conjunction with FIG. 5 is shown in the system 1450 of FIG. 6, which shows a patient 12 sleeping with an implantable Monitor 1458 and/or optional therapy device as described above in connection with the above-described systems. The implantable device 1458, upon detection of a neurological event may alert a remote monitoring location via local remote box 1452 (as described in U.S. Pat. No. 5,752,976), telephone 1454 and phone lines 1456 or the patient's care provider via an RF link 1432 to a pager-sized remote monitor 1460 placed in other locations in the house or carried (i.e., belt worn) by the care provider 1462. The remote caregiver monitor 1460 may include audible buzzes/tones/beeps, vocal, light and/or vibration to alert the caregiver 1462 of patient's monitor in an alarm/alert condition. The RF link may include RF portable phone frequencies, power line RF links, HomeRF, Bluetooth, ZigBee, WIFI, MICS band (medical implant communications service), or any other interconnect methods as appropriate.
  • Probabalistic Treatment Therapy
  • Suppose that a subject with seizures is being treated with an open loop control program. This subject may be simultaneously monitored using some means to log seizures. Example means include but are not limited to:
      • a. Quantifying the signal's seizure content using a method such as the algorithm in U.S. Pat. No. 5,995,868, without necessarily using the output to effect changes in real-time;
      • b. Logging time of seizure occurrences as well as brain state (e.g., awake); physical state (e.g., inactive); cognitive status (e.g., inattentive); metabolic status (e.g., blood glucose concentration); brain and body temperature; time from previous seizure(s); previous seizure(s)' intensity, severity and spread; and exposure to precipitants (e.g., light as measured using a light meter), without necessarily using the data to effect changes in real-time. Other markers of cerebral excitability such as GABA and glutamate concentrations and others listed in U.S. Pat. No. 6,934,580 may be included in the estimation of seizure probability; and/or
      • c. an event button with clock and memory.
  • Let t=time elapsed since beginning of delivery of a particular therapy program. Let {ti|i=1, 2, . . . } be a sequence of reference time points (“fiducial times”). Let tREL=t (mod max {ti|ti<=t}). Here tREL corresponds to the time elapsed since the most recent fiducial time. Examples:
      • a. ti=sequence of times corresponding to midnight on each day of monitoring. Then tREL is simply the time of day.
      • b. ti=sequence of times corresponding to beginning of menses in a female subject. Then tREL is the time in the subject's menstrual cycle.
      • c. ti=sequence of times corresponding to beginning of each administration of treatment or intervention. Then tREL is the time elapsed since the beginning of the last stimulation.
      • d. ti=sequence of seizure start (or end) times. Then tREL is the time elapsed since the start (resp., end) of the last seizure.
  • At any point in time, the probability of a seizure occurring is given by P(t)=P(Sz occurring at time t). Knowing P(t) would be of value in treating epilepsy. The inventors have developed a framework that does not rely on conventional on-line, real-time seizure detection or prediction but utilizes available information (history) to issue warnings and/or deliver therapy based on this developed probability function (as opposed to specific, binary, event detections). This probability function and related decisions of whether or not to issue a warning or deliver therapy can incorporate useful dependency of factors such as type of present activity and its inherent risk of injury, social embarrassment, and importance to preserve cognitive functions.
  • For any relative time, τ in Range {tREL}, given a reasonable length of monitoring, T, of the subject utilizing the current control program, one may compute and use the empirical probability of a seizure occurring at any point in time for this subject as:
    pE(τ; T)=(# of seizures with t REL=τ)/(# of times t REL=τ).
  • This “empirical probability density of seizures relative to time with respect to a fiducial sequence” is an approximation of the unknown probability of interest, namely, P(Sz occurring at time tREL=τ)
  • This empirical probability function can be used to compare one therapy control program against another (or against the untreated subject) in order to determine which is more effective and enables adjustment of therapy to improve efficacy.
  • ILLUSTRATIVE EXAMPLES
  • As depicted in FIG. 7, the probability of seizure occurrence is known to change as a function of time of day (from Osorio I, Frei M G, Manly B F J, Sunderam S, Bhavaraju N C, and Wilkinson S B. J Clin Neurophysiol. 2001 November; 18(6):533-44). Moreover, it is known that some patients are much more likely to have seizures while they are asleep (“nocturnal epilepsy”). By examining seizure frequency of occurrence as a function of time of day, one can determine the effect of circadian variations on seizures for a particular subject and use this information to better control their seizures as illustrated in the following example.
  • Example 1
  • Suppose a subject with primarily nocturnal seizures is monitored continuously for one month (or some period of time that yields a representative or useful sample) with no therapy enabled, and then for a second month (or other period), while being treated with an open loop control program that consists of 5 mA of stimulation at 100 Hz for 1 minute every 10 minutes (i.e., on 1 minute, off 9 minutes). Using time-of-day in generating tREL (as in above example), the graphs in FIG. 8 illustrate PE(τ) for months 1 (solid) and 2 (dash-dot), respectively. In this example, it is apparent that the therapy program had a seizure-reduction effect during the night, but may have increased seizure frequency during the day. Given this information, the user (subject or caretaker) may improve the overall efficacy of therapy by developing a new control program that is obtained by combining the approaches to produce a second control program that is equal to the previous one (on 1 minute, off 9 minutes) during the night, but is off completely between 8:30 and 15:30. Under the assumption that the effect of therapy is relatively instantaneous and lacking significant temporal carry-over effect, this revised control can be expected to result in improved therapy for the subject. While one skilled in the art will appreciate that the aforementioned assumptions need not be valid, the information obtained from the method allows the user to quantify the linearity of the response and the size and duration of the carry-over effect and to suitably modify the control program.
  • FIG. 9 depicts observed changes in seizure duration and intensity as a function of time from onset of stimulation (from S. Sunderam et al., Brain Research 918 (2001) 60-66). In another embodiment, the times of stimulation are used as fiducial times to examine the effect on seizure longevity and optimize the stimulation parameters. Seizure probability and severity may also be estimated as a function of time of delivery of therapy (such as electrical stimulation) and may depend upon other relevant parameters such as intensity, duration, frequency, stimulation polarity, etc.
  • Example 2
  • Consider a subject that is being treated with a closed-loop stimulation program. For example, after a period of no therapy, the treatment program provides for 2.5 s of continuous stimulation to the anterior thalamic nucleus, triggered by every other seizure detection (generated by an automated seizure detection algorithm). The subject continues to have seizures, so the stimulation duration is increased to 30 s of continuous stimulation, administered to the same brain location, again triggered by every other seizure detection. After a period of time, the monitoring data is collected and analyzed as described above with the fiducial times equal to the starting time of each stimulation. The corresponding probabilities of seizure survival, relative to elapsed time from start of stimulation, are shown in FIGS. 10 and 11. In this manner, the system enables the user to determine the duration of stimulation that has optimal effect in terms of seizure reduction (approximately 15 s), beyond which efficacy is not improved further.
  • FIG. 10, depicts a subject where every other seizure is treated by 2.5 s stimulation beginning at seizure onset. The curves show probability of being in seizure as a function of time from beginning of seizure. The upper curve indicates probability for stimulated seizures, and the lower curve represents those seizures that were not stimulated. No significant difference is evident.
  • In FIG. 11, depicts a subject where every other seizure is treated by 30 s stimulation beginning at seizure onset. The curves show probability of being in seizure as a function of time from beginning of seizure. The lowest curve indicates probability for stimulated seizures, the middle curve indicates probability for those seizures that were not stimulated, and the highest curve indicates the baseline probability from pre-treatment phase recordings.
  • Example 3
  • A subject that is being treated with an open-loop therapy may be equipped with a device for intensive continuous monitoring of biological signals (such as EEG or EKG), which will detect and quantify features of these signals (e.g., epileptiform brain activity or heart rate changes) associated with seizures for a period of time (e.g., 48 hr). The monitored activity will be analyzed with respect to some fiducial time sequence (e.g., times of onset of stimulation delivery, times of changing of stimulation intensity, time of day, etc.) and the empirical probability density of seizures relative to time with respect to the fiducial sequence is generated.
  • FIG. 12 provides an illustration of such information, in which the fiducial times are the times of onset of trains of electrical stimulation delivered for 30 s every 10 minutes. From this analysis it becomes apparent that the open-loop stimulation program provides very little immediate effect, but has a carry-over, protective effect against seizures that lasts for 2.5 minutes beyond the end of stimulation. This implies that the open-loop stimulation program should be altered to provide 30 s of stimulation every 3 minutes. Similar subsequent analysis can be used to determine the potential benefit of additional fine-tuning of the therapy program.
  • The approach illustrated in the above example can be indirectly tested in future open-loop trials, by measuring changes in seizure frequency over pre-specified time periods as a function of stimulation cycle length (e.g., 1 min ON-5 min OFF vs. 1 min ON-2.5 min OFF); greater reductions in seizure frequency with shorter off cycles than with longer off cycles would demonstrate the direction and benefit of utilizing “carry-over” effect information in seizure prophylaxis or abatement. Applicants note that potentially greater benefits may be provided with stimulation applied at relatively high frequencies. For example, Applicants have determined that applying stimulation pulses at frequencies such as 175 Hz to the anterior thalamic nuclei (or neighboring locations) may allow for substantial reductions in seizures in patients that suffer from otherwise inoperable pharmaco-resistant seizures if the stimulation pulses are provided at a rate of one minute stimulation-on, five minutes stimulation-off. High frequency electrical stimulation, defined as 100 Hz minimum, may (1) induce synaptic plasticity in the form of short-term depression, long-term depression, or both; (2) upregulate glutamic acid decarboxylase and downregulate calcium-and calmodulin-dependent protein kinase II, the net effect of which is to enhance inhibition at or near the stimulated site. In addition, high frequency electrical stimulation increases the seizure threshold in the rat pentylenetetrazol model when delivered to the anterior thalamic nuclei and therefore may have a similar effect in humans. Such a stimulation signal may be applied with an intensity of 5 volts and an initial round of closed-loop testing may be used to determine the stimulation signal's parameters such as shape, duration, amplitude and any other signal parameter that may be controlled.
  • The intervention delivered by the probabilistic closed-loop methods disclosed herein may be tailored for individual or subject-specific warning and/or treatment based on the frequency and/or severity of seizures, circadian patterns, occupational hazards, social factors, employment demands, etc.
  • The probabilistic closed-loop approach, which encompasses the concept of “intelligent open-loop,” may be used to issue “graded” or incremental warnings and/or therapy. For example, the seizure probability in a given patient is estimated to be 40% at a given time. This probability estimate may trigger a warning (vibration or sound) that is half as intense as one associated with a probability twice as high (i.e., 80%). The intensity or type of warning in this embodiment changes as a function of changes in probability, either decreasing or increasing as a function of its value. Further, a warning associated with a certain probability estimate may change as a function of risk of injury or of social embarrassment should a seizure occur; a 40% seizure probability in a patient sitting in a chair at home would be much less intense than if the subject was operating a vehicle. Temperature sensors, accelerometers and/or EKG among other means, may be used to determine the level of activity (sedentary vs. in motion) and its relative duration to automatically adjust the level or type of warning. Operation of power equipment or of vehicles may be factored into the warning scale by the patient simply pressing a button prior to initiating these activities. Cars or power equipment may be also equipped with devices that upgrade the warning level as they are turned ON and a disabling device that communicates with the patient's device may be activated should the seizure probability be at an unsafe level. An identical approach may be taken for therapy: The type of therapy and parameters/dose used when the seizure probability is 40% may be different that when it is 80% or when the subject changes activity from a low to a high risk for injury.
  • In other embodiments, other thalamic stimulation targets may be applied for treatment of the neurological disorder, including particularly mesial temporal and mesial frontal intractable epilepsies. These targets include anterior thalamic nuclei, nucleus Reticulatus polaris, nucleus Latero-polaris, nucleus Antero-medialis, nucleus Ventro-oralis Internus, nucleus Antero-principalis and nucleus Lateropolaris. It is noted that while the anterior thalamic nuclei is a known target for stimulation, success has been experienced when stimulating neighborhood targets. Thus, in an embodiment a stimulation target may be a region, which is defined as more than one nucleus or thalamic structure, rather than a single thalamic nucleus or structure. In addition, another possible target is the Campus Forelli Pars H2, which is not a direct neighbor of the anterior thalamic nuclei. Other targets are also contemplated and would vary depending on the type of disorder.
  • While it has been determined that neighborhood targets may also provide suitable candidates so as to allow the physician implanting the electrode in the target greater latitude in the selection of the target, for certain treatment procedures it is desirable to stimulate the same target in both the right and left hemisphere of the patient's brain. Therefore, the evoked response methodology discussed below provides certain benefits when attempting to implant electrodes in particular regions and/or locations of the brain.
  • In general, evoked responses are generated by applying a stimulation pulse with an implanted target electrode and measuring the resultant response at other electrodes such as scalp electrodes or other depth electrodes. Measurements of amplitude, latency and conduction velocity provide information that allows a determination of the location of the implanted electrode being used to stimulate. Additionally, the morphology and polarity of the responses provide information about the uniformity of electrode placement intra- and inter-individually since they depend on the nature, location and orientation of the current sources, as well as on volume conduction characteristics which are determined by the electrical and geometric properties of the tissue. This location information also provides information on the connection that the electrode stimulation site has to the desired treatment site, thus indicating whether the stimulation site is a neighboring site of the desired treatment site. In an embodiment, evoked responses may be used to assess the precision of lead placement intra- and inter-individually. This complements MRI or other imaging based techniques and is particularly useful for targets that as the ATN, than unlike the STN (for treatment of movement disorders) appear to lack easily identifiable electrophysiological markers. Accurate in-vivo localization of electrodes/contacts and identification of functional or electrographic target markers loom as challenges that must be successfully addressed to identify, with reproducible accuracy in humans, structures with seizure gating capabilities and properly assess the therapeutic value/ratio of open- or closed-loop electrical stimulation. Although evoked responses techniques as used in a recent investigation do not provide direct information about lead localization, they may be used (a) to indirectly determine if the Epileptogenic Zone(s) and the leads'targets share anatomical connections; and (b) as tools to assess intra- as well as inter-individual uniformity/precision of lead placement. Applicants have determined that the intra- and inter-individual differences in evoked responses in these subjects may accurately predict the probable differences in lead location. The basis for this claim is that the potential or waveform (defined by polarity, morphology and amplitude) at any location in the brain may vary depending on: (1) the nature, location and orientation of the current sources; and (2) volume conduction characteristics which are determined by the electrical and geometric properties of the tissue. That is, potentials or waveforms of different amplitude, morphology and polarity, recorded from the same site, are not generated by the same current source or structure. Indirect or direct electrical stimulation of brain structures generates reproducible waves or oscillations (i.e., evoked responses), that may be recorded from the scalp (or intra-cerebrally) and have shapes and latencies that are unique for each structure. For example, the responses generated by stimulation of structures involved in the processing of sensory signals, have characteristic shapes and latencies that are highly similar among different subjects and are easily distinguishable, from those generated by structures involved in processing acoustic stimuli which are also highly similar inter-individually. It follows, therefore, that direct or indirect stimulation of the same structure in each cerebral hemisphere elicits highly similar, if not identical, reproducible responses that may be recorded from the scalp, using electrodes placed according to the 10-20 system, or, any other standardized system of electrode placement. For example, bi-phasic square pulses (0.7 Hz; 0.1 ms/phase; 5.1 mA/phase) may be applied to electrodes near the planned treatment area and the responses record so as to determine the location of the electrodes. These responses may be also reliably and reproducibly recorded intra-cerebrally from structures connected to those being stimulated. Differences in evoked responses elicited from relatively selective unilateral electrical or chemical stimulation of a given cerebral structure, compared to a) responses elicited by stimulation of the homologous contra-lateral structure or b) responses elicited in other individuals, suggest the structures being stimulated are different. Thus, it can be determined that the leads through which the currents are being passed are not in homologous structures or regions. This allows safe, repetitive and accurate assessment of precision of placement without the need to resort to magnetic resonance or computerized tomography. In addition, precise determination of the placement of the leads can also reduce the subjectivity inherent to visual localization of leads since evoked responses are quantitative.
  • It should be noted that evoked responses may be used to find out if the structure where the stimulation electrode is being placed has functional connectivity with the remote area whose abnormal activity is being controlled or abated. The presence of reproducible evoked responses in the abnormal or treatment area, defined as responses with identical latency, morphology and amplitude obtained from at least 2 separate stimulation trials, is strong evidence that the stimulation area and the abnormal area have functional connectivity. Furthermore, placement of the stimulation electrode may be optimized by monitoring changes in latency, amplitude and morphology in response to small changes in the position (in the x, y or z planes) of the electrode or by changing the part or contact of that electrode through which currents are passed. If stimulation parameters are kept constant and a change in the position of the contact and/or a change in the contact provides a decreases in latencies and/or increases in amplitude without changes in overall morphology then the change indicates improved placement. Evoked responses may be also used to find out if a stimulation target has functional connectivity with structures in the opposite hemisphere. This has important practical and clinical applications: If a structure in one hemisphere has functional connectivity with ipsi-lateral and contra-lateral homologous structures, stimulation of one side may suffice, or intermittent stimulation of the two sides may be alternated to provide full time protection. In other words, the total stimulation energy may be reduced because only side is stimulated at a time. This can extend the life of an implantable medical device with a limited power source and can also potentially reduce any negative cognitive effects that the stimulation might have.
  • FIG. 13 illustrates an embodiment of implanting and locating electrodes using evoked responses. In step 410 an electrode is positioned in a first hemisphere of the patient's brain. In an embodiment, the electrode may be shaped to stimulate more than one target site (for example, may be shaped like a shaft) and in another embodiment the electrode may be one of a plurality of electrodes in an array on a lead.
  • In step 420, a stimulation pulse is applied and the evoked response measured. In step 320, the evoked response is compared to an evoked response of an electrode positioned in a desired location, either in the current patient or in another patient. If the electrode is not in the desired position, steps 410 and 420 are repeated. It should be noted that in an embodiment where the electrode is one of a plurality of electrodes in an array, some portion of the electrodes may be selected and stimulated and step 420 may be repeated for each contact that is selected. As can be appreciated, in such an embodiment there may be no need to adjust the position of the lead if the first electrode is not properly positioned, rather the position of the selected contact on the lead can be changed until an electrode is determined to be positioned in a desired location. It should be noted that in a situation where a region is the intended target, the location of the first electrode is acceptable as long as the location is within the target region.
  • Once the first electrode is properly positioned, a second electrode is positioned in a second hemisphere in step 440. For example, if the first electrode is positioned in the left hemisphere, then the second electrode may be positioned in the right hemisphere. In step 450 the a stimulation pulse is applied to the second electrode and in step 460 a check is made to see if the location of the second electrode correspond to the position of the first electrode. If the location of the second electrode is determined to not match the desired location, steps 440-460 may be repeated. Therefore, in an embodiment the position of the second electrode can be made to correspond to the position of the first electrode by ensuring the evoked response of the second electrode is substantially identical to the evoked response of the first electrode.
  • It should be noted that modifications and additions to the steps of the process depicted in FIG. 13 are contemplated. For example, if the second electrode is one of a portion of electrodes in an array, the positioning of the second electrode can be simply selecting a different electrode from the array of electrodes. In addition, if the evoked response is determined to match an evoked response associated with a particular location, an indication, which may be textual or graphical, can be provided on a display so that the person implanting the electrode has a visual feedback on the location of the electrode. Therefore, the depicted process is representative and is not intended to be limiting unless otherwise noted.
  • FIG. 14 illustrates an embodiment of applying open-loop stimulation in accordance with one or more embodiments of the present invention. First in step 510, a plurality of electrodes is implanted at the desired location. It should be noted that precise electrode placement is not an easy task; therefore, a check may be made to determine the location of a plurality of implanted electrodes during the implanting process as discussed above in FIG. 13. It should be noted that plurality of electrodes may be situated in an array and may be situated on more than one lead. In step 520, an initial analysis is conducted with the electrodes. This analysis may use the probabilistic algorithms discussed above to determine stimulation parameters for reducing the occurrence of seizures when stimulation is applied at the one or more electrodes. It should be noted that using multiple electrodes has the advantage of potentially being able to stimulate a greater volume of brain tissue and, therefore, the application of a stimulation pulse to two or more electrodes may be desirable for certain types of treatment.
  • Once the parameters are determined, an implantable medical device may be implanted in step 530. It should be noted that for situations where open-loop stimulation is being used, the implanted medical device does not need to sense neurological signals and does not have to store events in an on-board memory. However, if desired, the stimulation device may also include recording features so that sensed signals may be analyzed at a later time. In addition, the implantable medical device may also be configured to record events, such as seizures, generated by a user actuating a programmer. In such a configuration the implantable medical device may communicate via telemetry in a known manner.
  • In step 550, the implantable medical device begins to provide stimulation in an open-loop fashion. In an embodiment, the stimulation may be bi-phasic at a high frequency such as 175 Hz and the electrodes that are selected may be the cathode (−) and the device case, which may be in the patient's chest, the anode (+) (a “monopolar” type configuration). Such a configured allows the electrodes that are in the proper location to encompass as much of the stimulation target as possible. In an embodiment the stimulation may be at an intensity of 5 volts with a repeating pattern of a period of one minute of stimulation followed by five minutes of no stimulation. It has been determined that, while other patterns are possible, such a pattern is well tolerated in initial patient studies and has a substantially beneficial effect on the reduction of seizures while having minimal or at least an acceptable impact on cognitive and motor-sensory functionality so as to improve the patient's quality of life.
  • In step 560, analysis is conducted to determine the efficacy of the treatment program. In an embodiment where the implanted medical device detects and stores events such as seizures, the information may be downloaded from the implanted device in a known manner and analyzed. As can be appreciated, with a suitable relay system this process can be initiated and conducted remotely. The analysis may include a determination of the reduction in seizure frequency and/or severity as well as an evaluation of cognitive and motor-sensory skills to determine a more complete picture of the effects of the treatment.
  • As can be appreciated, additional steps may be added and steps may be omitted or reordered as desired. For example, the implantable medical device may be implanted and first used in a closed-loop configuration to determine the desired stimulation parameters and/or the location of the electrodes and then be switched to an open-loop stimulation mode to conserve power.
  • The usefulness of the invention should be apparent to one skilled in the art. The use of any and all examples or exemplary language herein (e.g., “such as”) is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
  • The present invention has sometimes been described in terms of preferred and illustrative embodiments thereof. Numerous other embodiments, modifications and variations within the scope and spirit of the appended claims will occur to persons of ordinary skill in the art from a review of this disclosure.

Claims (25)

1. A method of treating a patient with a neurological disorder, comprising:
(a) implanting a first electrode approximate a first target site in a first hemisphere of the patient's brain;
(b) determining an evoked response of the first electrode;
(c) implanting a second electrode in a location approximate a second target site in a second hemisphere of the patient's brain; and
(d) verifying the location of the second electrode corresponds to the location of the first electrode by using an evoked response of the second electrode.
2. The method of claim 1, wherein the verify in (d) comprises
(i) determining the evoked response of the second electrode; and
(ii) in response to the evoked response of the second electrode not corresponding to the evoked response of the first electrode, adjusting the position of the second electrode until the evoked response of the second electrode does correspond to the evoked response of the first electrode.
3. The method of claim 1, further comprising:
(e) adjusting a position of the first electrode in response to the evoked response.
4. The method of claim 1, wherein the first target site is a region.
5. The method of claim 1, wherein the evoked response comprises parameters associated with amplitude, latency, conduction velocity, number of peaks, polarity and shape.
6. The method of claim 1, wherein the first target site is comprises a location selected from a list consisting of anterior thalamic nuclei, nucleus Reticulatus polaris, nucleus Latero-polaris, nucleus Antero-medialis, nucleus Ventro-oralis Internus, nucleus Antero-principalis, nucleus Lateropolaris and Campus Forelli Pars H2.
7. The method of claim 1, further comprising:
(e) verifying a location of the first electrode corresponds a desired location associated with a treatment area.
8. The method of claim 7, wherein the verifying in (e) comprises:
(i) obtaining a reproducible evoked response with well defined latency, amplitudes and morphology in at least two separate stimulation trials;
(ii) comparing the evoked response to an expected evoked response; and
(iii) in response to a determination that the evoked response does not correspond to the expected evoked response, adjusting the position of the first electrode until the evoked response of the first electrode does correspond to the expected evoked response.
9. The method of claim 1, further comprising:
(e) implanting an implantable medical device in the patient; and
(f) applying a closed-loop stimulation pattern to the first and second electrodes.
10. The method of claim 9, wherein the applying open-loop stimulation pattern in (f) comprises:
(i) configuring the first and second electrode as a cathode; and
(ii) configuring a case of the implantable medical device as an anode.
11. The method of claim 10, wherein the applying of open-loop stimulation in (f) comprises:
(iii) providing stimulation at between 145 Hz and 200 Hz in a repeating pattern that includes one minute of stimulation followed by five minutes of no stimulation.
12. The method of claim 11, wherein the stimulation is applied at 175 Hz at an intensity of 5 volts.
13. A method of treating a patient with a neurological disorder, comprising:
(a) implanting a plurality of electrodes approximate a target region of the patient's brain;
(b) verifying the location of at least one of the plurality of electrodes using an evoked response;
(c) determining stimulation parameters using the implanted electrodes and a closed-loop detection algorithm;
(d) coupling the plurality of electrodes to an implantable medical device; and
(e) applying open-loop stimulation to the plurality of electrodes with the implanted medical device based on the determined stimulation parameters.
14. The method of claim 13, wherein the verifying of the location in (b) comprises comparing the morphology, latency and polarity of the evoked response to determine the location of the implanted electrode.
15. The method of claim 13, wherein the applying of open-loop stimulation comprises:
(i) configuring the plurality of electrodes as a cathode; and
(ii) configuring a case of the implantable medical device as an anode.
16. The method of claim 13, wherein the evoked response is done while implanting the plurality of electrodes.
17. The method of claim 16, wherein the evoked response is measured using scalp electrodes.
18. The method of claim 16, wherein the evoked response is measured using intracranial electrodes.
19. The method of claim 13, wherein the verifying the location of the at least one electrode includes a determination of functionality connectivity between a structure being stimulated by the electrode and one of an ipsilateral and a contralateral structure, and wherein the applying of the open-loop stimulation stimulates a single side.
20. The method of claim 13, wherein the verifying the location of the at least one electrode includes a determination of functionality connectivity between a structure being stimulated by the electrode and one of an ipsilateral and a contralateral structure, and wherein the applying of the open-loop stimulation alternates stimulation between sides.
21. A computer readable medium comprising computer readable instructions, comprising:
(a) receiving an evoked response generated by applying a stimulation pulse applied to an implanted electrode;
(b) determining that the evoked response matches an known evoked response; and
(c) providing an indication that the evoked response matches the known evoked response.
22. The computer readable medium of claim 21, wherein the indication is rendered on a display.
23. The method of claim 22, wherein the indication provides information regarding a location of the implanted electrode.
24. A method of determining the existence of functional connectivity between a stimulation target and a treatment area, comprising:
(a) implanting a first electrode in the stimulation target;
(b) implanting a second electrode in the treatment area;
(c) stimulating the first electrode with an electrical pulse;
(d) obtaining an evoked response from the second electrode; and
(e) if the evoked response is not reproducible, repositioning the first electrode and repeating (c)-(d) until a reproducible evoked response is obtained from the second electrode.
25. The method of claim 24, wherein the treatment area comprises an abnormal brain area.
US11/624,590 2006-03-10 2007-01-18 Evoked Response to Stimulation Abandoned US20070244407A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/624,590 US20070244407A1 (en) 2006-03-10 2007-01-18 Evoked Response to Stimulation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78095406P 2006-03-10 2006-03-10
US11/380,752 US8209018B2 (en) 2006-03-10 2006-04-28 Probabilistic neurological disorder treatment
US11/624,590 US20070244407A1 (en) 2006-03-10 2007-01-18 Evoked Response to Stimulation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/380,752 Continuation-In-Part US8209018B2 (en) 2006-03-10 2006-04-28 Probabilistic neurological disorder treatment

Publications (1)

Publication Number Publication Date
US20070244407A1 true US20070244407A1 (en) 2007-10-18

Family

ID=38370450

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/380,752 Active 2027-10-12 US8209018B2 (en) 2006-03-10 2006-04-28 Probabilistic neurological disorder treatment
US11/624,590 Abandoned US20070244407A1 (en) 2006-03-10 2007-01-18 Evoked Response to Stimulation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/380,752 Active 2027-10-12 US8209018B2 (en) 2006-03-10 2006-04-28 Probabilistic neurological disorder treatment

Country Status (2)

Country Link
US (2) US8209018B2 (en)
WO (1) WO2007106343A2 (en)

Cited By (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080027515A1 (en) * 2006-06-23 2008-01-31 Neuro Vista Corporation A Delaware Corporation Minimally Invasive Monitoring Systems
US20080183097A1 (en) * 2007-01-25 2008-07-31 Leyde Kent W Methods and Systems for Measuring a Subject's Susceptibility to a Seizure
US20080183096A1 (en) * 2007-01-25 2008-07-31 David Snyder Systems and Methods for Identifying a Contra-ictal Condition in a Subject
US20080255582A1 (en) * 2007-04-11 2008-10-16 Harris John F Methods and Template Assembly for Implanting an Electrode Array in a Patient
US7869885B2 (en) 2006-04-28 2011-01-11 Cyberonics, Inc Threshold optimization for tissue stimulation therapy
US7869867B2 (en) 2006-10-27 2011-01-11 Cyberonics, Inc. Implantable neurostimulator with refractory stimulation
US7962220B2 (en) 2006-04-28 2011-06-14 Cyberonics, Inc. Compensation reduction in tissue stimulation therapy
US7974701B2 (en) 2007-04-27 2011-07-05 Cyberonics, Inc. Dosing limitation for an implantable medical device
US7996079B2 (en) 2006-01-24 2011-08-09 Cyberonics, Inc. Input response override for an implantable medical device
US8036736B2 (en) 2007-03-21 2011-10-11 Neuro Vista Corporation Implantable systems and methods for identifying a contra-ictal condition in a subject
US8150508B2 (en) 2006-03-29 2012-04-03 Catholic Healthcare West Vagus nerve stimulation method
US8204603B2 (en) 2008-04-25 2012-06-19 Cyberonics, Inc. Blocking exogenous action potentials by an implantable medical device
WO2012097872A1 (en) * 2011-01-20 2012-07-26 Widex A/S Personal eeg monitoring device with electrode validation
US8239028B2 (en) 2009-04-24 2012-08-07 Cyberonics, Inc. Use of cardiac parameters in methods and systems for treating a chronic medical condition
US8260426B2 (en) 2008-01-25 2012-09-04 Cyberonics, Inc. Method, apparatus and system for bipolar charge utilization during stimulation by an implantable medical device
US8295934B2 (en) 2006-11-14 2012-10-23 Neurovista Corporation Systems and methods of reducing artifact in neurological stimulation systems
US8337404B2 (en) 2010-10-01 2012-12-25 Flint Hills Scientific, Llc Detecting, quantifying, and/or classifying seizures using multimodal data
US8382667B2 (en) 2010-10-01 2013-02-26 Flint Hills Scientific, Llc Detecting, quantifying, and/or classifying seizures using multimodal data
US8417344B2 (en) 2008-10-24 2013-04-09 Cyberonics, Inc. Dynamic cranial nerve stimulation based on brain state determination from cardiac data
US8452387B2 (en) 2010-09-16 2013-05-28 Flint Hills Scientific, Llc Detecting or validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex
US8457747B2 (en) 2008-10-20 2013-06-04 Cyberonics, Inc. Neurostimulation with signal duration determined by a cardiac cycle
US20130184781A1 (en) * 2010-07-06 2013-07-18 Emad N. Eskandar Brain Stimulation for Enhancement of Learning, Motivation, and Memory
US8562524B2 (en) 2011-03-04 2013-10-22 Flint Hills Scientific, Llc Detecting, assessing and managing a risk of death in epilepsy
US8565867B2 (en) 2005-01-28 2013-10-22 Cyberonics, Inc. Changeable electrode polarity stimulation by an implantable medical device
US8562523B2 (en) 2011-03-04 2013-10-22 Flint Hills Scientific, Llc Detecting, assessing and managing extreme epileptic events
US8562536B2 (en) 2010-04-29 2013-10-22 Flint Hills Scientific, Llc Algorithm for detecting a seizure from cardiac data
US8588933B2 (en) 2009-01-09 2013-11-19 Cyberonics, Inc. Medical lead termination sleeve for implantable medical devices
US8641646B2 (en) 2010-07-30 2014-02-04 Cyberonics, Inc. Seizure detection using coordinate data
US8649871B2 (en) 2010-04-29 2014-02-11 Cyberonics, Inc. Validity test adaptive constraint modification for cardiac data used for detection of state changes
US8679009B2 (en) 2010-06-15 2014-03-25 Flint Hills Scientific, Llc Systems approach to comorbidity assessment
US8684921B2 (en) 2010-10-01 2014-04-01 Flint Hills Scientific Llc Detecting, assessing and managing epilepsy using a multi-variate, metric-based classification analysis
US8725239B2 (en) 2011-04-25 2014-05-13 Cyberonics, Inc. Identifying seizures using heart rate decrease
US8786624B2 (en) 2009-06-02 2014-07-22 Cyberonics, Inc. Processing for multi-channel signals
US20140213926A1 (en) * 2013-01-25 2014-07-31 Medtronic, Inc. Notification indicative of a change in efficacy of therapy
US8812098B2 (en) 2011-04-28 2014-08-19 Medtronic, Inc. Seizure probability metrics
US8831732B2 (en) 2010-04-29 2014-09-09 Cyberonics, Inc. Method, apparatus and system for validating and quantifying cardiac beat data quality
US8827912B2 (en) 2009-04-24 2014-09-09 Cyberonics, Inc. Methods and systems for detecting epileptic events using NNXX, optionally with nonlinear analysis parameters
US8849390B2 (en) 2008-12-29 2014-09-30 Cyberonics, Inc. Processing for multi-channel signals
US8868173B2 (en) 2011-04-20 2014-10-21 Medtronic, Inc. Method and apparatus for assessing neural activation
US8892207B2 (en) 2011-04-20 2014-11-18 Medtronic, Inc. Electrical therapy for facilitating inter-area brain synchronization
US8914119B2 (en) 2011-04-20 2014-12-16 Medtronic, Inc. Electrical brain therapy parameter determination based on a bioelectrical resonance response
US9050469B1 (en) 2003-11-26 2015-06-09 Flint Hills Scientific, Llc Method and system for logging quantitative seizure information and assessing efficacy of therapy using cardiac signals
US9056195B2 (en) 2013-03-15 2015-06-16 Cyberonics, Inc. Optimization of cranial nerve stimulation to treat seizure disorderse during sleep
US9126044B2 (en) 2010-04-15 2015-09-08 Cardiac Pacemakers, Inc. Autonomic modulation using transient response with intermittent neural stimulation
US9173609B2 (en) 2011-04-20 2015-11-03 Medtronic, Inc. Brain condition monitoring based on co-activation of neural networks
US9259591B2 (en) 2007-12-28 2016-02-16 Cyberonics, Inc. Housing for an implantable medical device
US9302109B2 (en) 2014-04-25 2016-04-05 Cyberonics, Inc. Cranial nerve stimulation to treat depression during sleep
US9314633B2 (en) 2008-01-25 2016-04-19 Cyberonics, Inc. Contingent cardio-protection for epilepsy patients
US9402550B2 (en) 2011-04-29 2016-08-02 Cybertronics, Inc. Dynamic heart rate threshold for neurological event detection
US20160279397A1 (en) * 2015-03-23 2016-09-29 Greatbatch Ltd. Apparatus and method for implanting an implantable device
US20160287127A1 (en) * 2015-04-06 2016-10-06 Forest Devices, Inc. Neuorological condition detection unit and method of using the same
US9504390B2 (en) 2011-03-04 2016-11-29 Globalfoundries Inc. Detecting, assessing and managing a risk of death in epilepsy
CN106390280A (en) * 2015-08-10 2017-02-15 华邦电子股份有限公司 Closed loop stimulating device and stimulating method thereof
US9585611B2 (en) 2014-04-25 2017-03-07 Cyberonics, Inc. Detecting seizures based on heartbeat data
US20170083668A1 (en) * 2012-01-20 2017-03-23 International Business Machines Corporation Method and apparatus providing an online diagnostic assistant tool
US9643019B2 (en) 2010-02-12 2017-05-09 Cyberonics, Inc. Neurological monitoring and alerts
US20170265764A1 (en) * 2014-11-24 2017-09-21 Ivan Osorio Subcortical (thalamic) automated seizure detection for contingent therapy delivery systems and methods
US9788744B2 (en) 2007-07-27 2017-10-17 Cyberonics, Inc. Systems for monitoring brain activity and patient advisory device
US9878161B2 (en) 2011-04-29 2018-01-30 Medtronic, Inc. Entrainment of bioelectrical brain signals
US10206591B2 (en) 2011-10-14 2019-02-19 Flint Hills Scientific, Llc Seizure detection methods, apparatus, and systems using an autoregression algorithm
US10220211B2 (en) 2013-01-22 2019-03-05 Livanova Usa, Inc. Methods and systems to diagnose depression
CN109475295A (en) * 2016-06-29 2019-03-15 皇家飞利浦有限公司 Method and apparatus for health equipment and wearable/implantable devices
US10448839B2 (en) 2012-04-23 2019-10-22 Livanova Usa, Inc. Methods, systems and apparatuses for detecting increased risk of sudden death
US10653883B2 (en) 2009-01-23 2020-05-19 Livanova Usa, Inc. Implantable medical device for providing chronic condition therapy and acute condition therapy using vagus nerve stimulation
US20200352468A1 (en) * 2008-10-15 2020-11-12 Nuvasive, Inc. Neurophysiologic Monitoring System and Related Methods
US11273283B2 (en) 2017-12-31 2022-03-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
US11406317B2 (en) 2007-12-28 2022-08-09 Livanova Usa, Inc. Method for detecting neurological and clinical manifestations of a seizure
US11452839B2 (en) 2018-09-14 2022-09-27 Neuroenhancement Lab, LLC System and method of improving sleep
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11786736B2 (en) 2021-03-18 2023-10-17 Boston Scientific Neuromodulation Corporation Methods and systems for lead movement detection and response in DBS therapy

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101611240B1 (en) 2006-10-25 2016-04-11 프로테우스 디지털 헬스, 인코포레이티드 Controlled activation ingestible identifier
EP2069004A4 (en) 2006-11-20 2014-07-09 Proteus Digital Health Inc Active signal processing personal health signal receivers
US20080161712A1 (en) 2006-12-27 2008-07-03 Kent Leyde Low Power Device With Contingent Scheduling
US9913593B2 (en) * 2006-12-27 2018-03-13 Cyberonics, Inc. Low power device with variable scheduling
KR101475666B1 (en) 2007-02-01 2014-12-23 프로테우스 디지털 헬스, 인코포레이티드 ingestible event marker systems
CN103066226B (en) 2007-02-14 2016-09-14 普罗透斯数字保健公司 There is the in-body power source of high surface area electrode
US8540632B2 (en) 2007-05-24 2013-09-24 Proteus Digital Health, Inc. Low profile antenna for in body device
US8961412B2 (en) 2007-09-25 2015-02-24 Proteus Digital Health, Inc. In-body device with virtual dipole signal amplification
US20090264789A1 (en) * 2007-09-26 2009-10-22 Medtronic, Inc. Therapy program selection
US8380314B2 (en) * 2007-09-26 2013-02-19 Medtronic, Inc. Patient directed therapy control
WO2009042170A1 (en) * 2007-09-26 2009-04-02 Medtronic, Inc. Therapy program selection
EP2211986B1 (en) 2007-10-16 2013-11-20 Medtronic, Inc. Therapy control based on a patient movement state
US20170188940A9 (en) 2007-11-26 2017-07-06 Whispersom Corporation Device to detect and treat Apneas and Hypopnea
EP2249908B1 (en) 2008-01-25 2014-01-01 Medtronic, Inc. Sleep stage detection
US20110251468A1 (en) * 2010-04-07 2011-10-13 Ivan Osorio Responsiveness testing of a patient having brain state changes
DK2313002T3 (en) 2008-07-08 2018-12-03 Proteus Digital Health Inc Data basis for edible event fields
JP5653918B2 (en) 2008-07-30 2015-01-14 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ (イーピーエフエル) Apparatus and method for optimized stimulation of neural targets
US8788064B2 (en) 2008-11-12 2014-07-22 Ecole Polytechnique Federale De Lausanne Microfabricated neurostimulation device
CN102341031A (en) 2009-01-06 2012-02-01 普罗秋斯生物医学公司 Ingestion-related biofeedback and personalized medical therapy method and system
EP2391264A4 (en) * 2009-02-02 2013-12-25 Neurostream Technologies General Partnership A method and device for the prevention of sudden unexpected death in epilepsy (sudep)
TWI517050B (en) 2009-11-04 2016-01-11 普羅托斯數位健康公司 System for supply chain management
US9770204B2 (en) * 2009-11-11 2017-09-26 Medtronic, Inc. Deep brain stimulation for sleep and movement disorders
JP2013512062A (en) 2009-12-01 2013-04-11 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ Microfabricated surface nerve stimulation device and methods of making and using the same
US8914115B2 (en) * 2009-12-03 2014-12-16 Medtronic, Inc. Selecting therapy cycle parameters based on monitored brain signal
WO2012074565A1 (en) * 2010-01-26 2012-06-07 University Of Utah Research Foundation Imaging-based identification of a neurological disease or a neurological disorder
US8099170B2 (en) 2010-03-19 2012-01-17 Medtronic, Inc. Electrical stimulation based on phase response mapping
EP2552536B1 (en) 2010-04-01 2016-06-08 Ecole Polytechnique Fédérale de Lausanne (EPFL) Device for interacting with neurological tissue
TWI557672B (en) 2010-05-19 2016-11-11 波提亞斯數位康健公司 Computer system and computer-implemented method to track medication from manufacturer to a patient, apparatus and method for confirming delivery of medication to a patient, patient interface device
WO2011150220A1 (en) * 2010-05-26 2011-12-01 Flint Hills Scientific, L.L.C. Quantitative multivariate analysis of seizures
US8951192B2 (en) * 2010-06-15 2015-02-10 Flint Hills Scientific, Llc Systems approach to disease state and health assessment
US8447406B2 (en) * 2010-06-29 2013-05-21 Medtronic, Inc. Medical method and device for monitoring a neural brain network
US9211411B2 (en) 2010-08-26 2015-12-15 Medtronic, Inc. Therapy for rapid eye movement behavior disorder (RBD)
EP2621333B1 (en) 2010-09-28 2015-07-29 Masimo Corporation Depth of consciousness monitor including oximeter
US20120136273A1 (en) * 2010-11-29 2012-05-31 Epilepsy Solutions, Llc Apparatus and method for monitoring and analyzing brainwaves
WO2012103224A1 (en) 2011-01-25 2012-08-02 Medtronic, Inc. Target therapy delivery site selection
JP2012239696A (en) * 2011-05-20 2012-12-10 Sony Corp Brain wave activation apparatus
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
CA2842952C (en) 2011-07-21 2019-01-08 Proteus Digital Health, Inc. Mobile communication device, system, and method
US10631760B2 (en) * 2011-09-02 2020-04-28 Jeffrey Albert Dracup Method for prediction, detection, monitoring, analysis and alerting of seizures and other potentially injurious or life-threatening states
US10595787B2 (en) 2011-10-14 2020-03-24 Flint Hills Scientific, Llc Apparatus and systems for event detection using probabilistic measures
WO2013056099A1 (en) * 2011-10-14 2013-04-18 Flint Hills Scientific, Llc Apparatus and systems for event detection using probabilistic measures
US9788779B2 (en) * 2013-03-14 2017-10-17 Flint Hills Scientific, L.L.C. Seizure detection based on work level excursion
WO2014197402A1 (en) * 2013-06-04 2014-12-11 Proteus Digital Health, Inc. System, apparatus and methods for data collection and assessing outcomes
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
EP4039190A1 (en) * 2014-01-30 2022-08-10 Flint Hills Scientific, LLC Seizure detection based on work level excursion
EP3476430B1 (en) 2014-05-16 2020-07-01 Aleva Neurotherapeutics SA Device for interacting with neurological tissue
US11311718B2 (en) 2014-05-16 2022-04-26 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
US9403011B2 (en) 2014-08-27 2016-08-02 Aleva Neurotherapeutics Leadless neurostimulator
US9474894B2 (en) 2014-08-27 2016-10-25 Aleva Neurotherapeutics Deep brain stimulation lead
US10154815B2 (en) 2014-10-07 2018-12-18 Masimo Corporation Modular physiological sensors
JP6295372B2 (en) * 2015-03-20 2018-03-14 株式会社東芝 A relay device comprising a first slot antenna and a second slot antenna for detecting and relaying a signal from an implantable medical device
WO2017134587A1 (en) 2016-02-02 2017-08-10 Aleva Neurotherapeutics, Sa Treatment of autoimmune diseases with deep brain stimulation
MX2019000888A (en) 2016-07-22 2019-06-03 Proteus Digital Health Inc Electromagnetic sensing and detection of ingestible event markers.
CA3070980C (en) 2017-07-25 2023-10-31 Seer Medical Pty Ltd Methods and systems for forecasting seizures
US20190060647A1 (en) 2017-08-31 2019-02-28 Medtronic, Inc. Sacral nerve stimulation
US10702692B2 (en) 2018-03-02 2020-07-07 Aleva Neurotherapeutics Neurostimulation device
US10765355B2 (en) 2018-04-27 2020-09-08 Medtronic, Inc. Monitoring bladder dysfunction using a probability function

Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3863625A (en) * 1973-11-02 1975-02-04 Us Health Epileptic seizure warning system
US5995868A (en) * 1996-01-23 1999-11-30 University Of Kansas System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject
US6343229B1 (en) * 1997-06-15 2002-01-29 Mario Siebler Device for measurement and analysis of brain activity of both cerebral hemispheres in a patient
US6374140B1 (en) * 1998-04-30 2002-04-16 Medtronic, Inc. Method and apparatus for treating seizure disorders by stimulating the olfactory senses
US20020103512A1 (en) * 2000-12-12 2002-08-01 Echauz Javier Ramon Adaptive method and apparatus for forecasting and controlling neurological disturbances under a multi-level control
US6560486B1 (en) * 1999-10-12 2003-05-06 Ivan Osorio Bi-directional cerebral interface system
US6594525B1 (en) * 1999-08-26 2003-07-15 Med-El Elektromedizinische Geraete Gmbh Electrical nerve stimulation based on channel specific sampling sequences
US20030139781A1 (en) * 2001-12-04 2003-07-24 Kerry Bradley Apparatus and method for determining the relative position and orientation of neurostimulation leads
US20030204219A1 (en) * 2002-04-29 2003-10-30 Frans Gielen Stimulation control for brain stimulation
US6678548B1 (en) * 2000-10-20 2004-01-13 The Trustees Of The University Of Pennsylvania Unified probabilistic framework for predicting and detecting seizure onsets in the brain and multitherapeutic device
US20040082984A1 (en) * 2002-10-11 2004-04-29 Ivan Osorio Multi-modal system for detection and control of changes in brain state
US6795737B2 (en) * 1998-04-30 2004-09-21 Medtronic Inc. Techniques for positioning therapy delivery elements within a spinal cord or a brain
US20040267152A1 (en) * 2003-02-26 2004-12-30 Pineda Jaime A. Method and system for predicting and preventing seizures
US20050004617A1 (en) * 2003-04-28 2005-01-06 Dawant Benoit M. Apparatus and methods of optimal placement of deep brain stimulator
US20050049650A1 (en) * 2000-10-30 2005-03-03 Medtronic, Inc. Method for treating obsessive-compulsive disorder with electrical stimulation of the brain internal capsule
US20050049649A1 (en) * 2002-10-21 2005-03-03 The Cleveland Clinic Foundation Electrical stimulation of the brain
US20050065427A1 (en) * 2003-09-12 2005-03-24 Magill Peter James Methods of neural centre location and electrode placement in the central nervous system
US20050165458A1 (en) * 2002-05-09 2005-07-28 Boveja Birinder R. Method and system to provide therapy for depression using electroconvulsive therapy(ECT) and pulsed electrical stimulation to vagus nerve(s)
US20050240242A1 (en) * 1998-08-05 2005-10-27 Dilorenzo Daniel J Closed-loop feedback-driven neuromodulation
US20050283201A1 (en) * 2004-05-04 2005-12-22 Andre Machado Methods of treating neurological conditions by neuromodulation of interhemispheric fibers
US20060015153A1 (en) * 2004-07-15 2006-01-19 Gliner Bradford E Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy
US20060058855A1 (en) * 2004-04-23 2006-03-16 Gill Steven S Deep brain stimulation
US20060212090A1 (en) * 2005-03-01 2006-09-21 Functional Neuroscience Inc. Method of treating cognitive disorders using neuromodulation
US20070129770A1 (en) * 2001-09-30 2007-06-07 Imad Younis Electrode System For Neural Applications
US7437196B2 (en) * 2004-11-12 2008-10-14 Northstar Neuroscience, Inc. Systems and methods for selecting stimulation sites and applying treatment, including treatment of symptoms of Parkinson's disease, other movement disorders, and/or drug side effects

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374382A (en) 1981-01-16 1983-02-15 Medtronic, Inc. Marker channel telemetry system for a medical device
US5052388A (en) 1989-12-22 1991-10-01 Medtronic, Inc. Method and apparatus for implementing activity sensing in a pulse generator
US5127404A (en) 1990-01-22 1992-07-07 Medtronic, Inc. Telemetry format for implanted medical device
US5782891A (en) 1994-06-16 1998-07-21 Medtronic, Inc. Implantable ceramic enclosure for pacing, neurological, and other medical applications in the human body
JP2000514682A (en) 1996-07-11 2000-11-07 メドトロニック・インコーポレーテッド Minimal invasive implantable device for monitoring physiological events
US6427086B1 (en) 1997-10-27 2002-07-30 Neuropace, Inc. Means and method for the intracranial placement of a neurostimulator
US5891180A (en) 1998-04-29 1999-04-06 Medtronic Inc. Interrogation of an implantable medical device using audible sound communication
WO2000010455A1 (en) 1998-08-24 2000-03-02 Emory University Method and apparatus for predicting the onset of seizures based on features derived from signals indicative of brain activity
US6304775B1 (en) 1999-09-22 2001-10-16 Leonidas D. Iasemidis Seizure warning and prediction
US7136695B2 (en) 2001-10-12 2006-11-14 Pless Benjamin D Patient-specific template development for neurological event detection
WO2003063684A2 (en) 2002-01-25 2003-08-07 Intellipatch, Inc. Evaluation of a patient and prediction of chronic symptoms

Patent Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3863625A (en) * 1973-11-02 1975-02-04 Us Health Epileptic seizure warning system
US5995868A (en) * 1996-01-23 1999-11-30 University Of Kansas System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject
US6343229B1 (en) * 1997-06-15 2002-01-29 Mario Siebler Device for measurement and analysis of brain activity of both cerebral hemispheres in a patient
US6374140B1 (en) * 1998-04-30 2002-04-16 Medtronic, Inc. Method and apparatus for treating seizure disorders by stimulating the olfactory senses
US6795737B2 (en) * 1998-04-30 2004-09-21 Medtronic Inc. Techniques for positioning therapy delivery elements within a spinal cord or a brain
US20050240242A1 (en) * 1998-08-05 2005-10-27 Dilorenzo Daniel J Closed-loop feedback-driven neuromodulation
US6594525B1 (en) * 1999-08-26 2003-07-15 Med-El Elektromedizinische Geraete Gmbh Electrical nerve stimulation based on channel specific sampling sequences
US6560486B1 (en) * 1999-10-12 2003-05-06 Ivan Osorio Bi-directional cerebral interface system
US6678548B1 (en) * 2000-10-20 2004-01-13 The Trustees Of The University Of Pennsylvania Unified probabilistic framework for predicting and detecting seizure onsets in the brain and multitherapeutic device
US20050049650A1 (en) * 2000-10-30 2005-03-03 Medtronic, Inc. Method for treating obsessive-compulsive disorder with electrical stimulation of the brain internal capsule
US20030158587A1 (en) * 2000-12-12 2003-08-21 The Trustees Of The University Of Pennsylvania Adaptive method and apparatus for forecasting and controlling neurological disturbances under a multi-level control
US20020103512A1 (en) * 2000-12-12 2002-08-01 Echauz Javier Ramon Adaptive method and apparatus for forecasting and controlling neurological disturbances under a multi-level control
US20070129770A1 (en) * 2001-09-30 2007-06-07 Imad Younis Electrode System For Neural Applications
US20030139781A1 (en) * 2001-12-04 2003-07-24 Kerry Bradley Apparatus and method for determining the relative position and orientation of neurostimulation leads
US20030204219A1 (en) * 2002-04-29 2003-10-30 Frans Gielen Stimulation control for brain stimulation
US20050165458A1 (en) * 2002-05-09 2005-07-28 Boveja Birinder R. Method and system to provide therapy for depression using electroconvulsive therapy(ECT) and pulsed electrical stimulation to vagus nerve(s)
US20040082984A1 (en) * 2002-10-11 2004-04-29 Ivan Osorio Multi-modal system for detection and control of changes in brain state
US20050049649A1 (en) * 2002-10-21 2005-03-03 The Cleveland Clinic Foundation Electrical stimulation of the brain
US20040267152A1 (en) * 2003-02-26 2004-12-30 Pineda Jaime A. Method and system for predicting and preventing seizures
US20050004617A1 (en) * 2003-04-28 2005-01-06 Dawant Benoit M. Apparatus and methods of optimal placement of deep brain stimulator
US20050065427A1 (en) * 2003-09-12 2005-03-24 Magill Peter James Methods of neural centre location and electrode placement in the central nervous system
US7582062B2 (en) * 2003-09-12 2009-09-01 Medical Research Council Methods of neural centre location and electrode placement in the central nervous system
US20060058855A1 (en) * 2004-04-23 2006-03-16 Gill Steven S Deep brain stimulation
US20050283201A1 (en) * 2004-05-04 2005-12-22 Andre Machado Methods of treating neurological conditions by neuromodulation of interhemispheric fibers
US20060015153A1 (en) * 2004-07-15 2006-01-19 Gliner Bradford E Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy
US7437196B2 (en) * 2004-11-12 2008-10-14 Northstar Neuroscience, Inc. Systems and methods for selecting stimulation sites and applying treatment, including treatment of symptoms of Parkinson's disease, other movement disorders, and/or drug side effects
US20060212090A1 (en) * 2005-03-01 2006-09-21 Functional Neuroscience Inc. Method of treating cognitive disorders using neuromodulation

Cited By (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11185695B1 (en) 2003-11-26 2021-11-30 Flint Hills Scientific, L.L.C. Method and system for logging quantitative seizure information and assessing efficacy of therapy using cardiac signals
US9050469B1 (en) 2003-11-26 2015-06-09 Flint Hills Scientific, Llc Method and system for logging quantitative seizure information and assessing efficacy of therapy using cardiac signals
US8565867B2 (en) 2005-01-28 2013-10-22 Cyberonics, Inc. Changeable electrode polarity stimulation by an implantable medical device
US9586047B2 (en) 2005-01-28 2017-03-07 Cyberonics, Inc. Contingent cardio-protection for epilepsy patients
US7996079B2 (en) 2006-01-24 2011-08-09 Cyberonics, Inc. Input response override for an implantable medical device
US9533151B2 (en) 2006-03-29 2017-01-03 Dignity Health Microburst electrical stimulation of cranial nerves for the treatment of medical conditions
US8280505B2 (en) 2006-03-29 2012-10-02 Catholic Healthcare West Vagus nerve stimulation method
US8660666B2 (en) 2006-03-29 2014-02-25 Catholic Healthcare West Microburst electrical stimulation of cranial nerves for the treatment of medical conditions
US8615309B2 (en) 2006-03-29 2013-12-24 Catholic Healthcare West Microburst electrical stimulation of cranial nerves for the treatment of medical conditions
US8738126B2 (en) 2006-03-29 2014-05-27 Catholic Healthcare West Synchronization of vagus nerve stimulation with the cardiac cycle of a patient
US9289599B2 (en) 2006-03-29 2016-03-22 Dignity Health Vagus nerve stimulation method
US8219188B2 (en) 2006-03-29 2012-07-10 Catholic Healthcare West Synchronization of vagus nerve stimulation with the cardiac cycle of a patient
US8150508B2 (en) 2006-03-29 2012-04-03 Catholic Healthcare West Vagus nerve stimulation method
US9108041B2 (en) 2006-03-29 2015-08-18 Dignity Health Microburst electrical stimulation of cranial nerves for the treatment of medical conditions
US7962220B2 (en) 2006-04-28 2011-06-14 Cyberonics, Inc. Compensation reduction in tissue stimulation therapy
US7869885B2 (en) 2006-04-28 2011-01-11 Cyberonics, Inc Threshold optimization for tissue stimulation therapy
US20080027515A1 (en) * 2006-06-23 2008-01-31 Neuro Vista Corporation A Delaware Corporation Minimally Invasive Monitoring Systems
US7676263B2 (en) * 2006-06-23 2010-03-09 Neurovista Corporation Minimally invasive system for selecting patient-specific therapy parameters
US20080033502A1 (en) * 2006-06-23 2008-02-07 Neurovista Corporation A Delaware Corporation Minimally Invasive System for Selecting Patient-Specific Therapy Parameters
US7869867B2 (en) 2006-10-27 2011-01-11 Cyberonics, Inc. Implantable neurostimulator with refractory stimulation
US8855775B2 (en) 2006-11-14 2014-10-07 Cyberonics, Inc. Systems and methods of reducing artifact in neurological stimulation systems
US8295934B2 (en) 2006-11-14 2012-10-23 Neurovista Corporation Systems and methods of reducing artifact in neurological stimulation systems
US9622675B2 (en) 2007-01-25 2017-04-18 Cyberonics, Inc. Communication error alerting in an epilepsy monitoring system
US20080183097A1 (en) * 2007-01-25 2008-07-31 Leyde Kent W Methods and Systems for Measuring a Subject's Susceptibility to a Seizure
US20080183096A1 (en) * 2007-01-25 2008-07-31 David Snyder Systems and Methods for Identifying a Contra-ictal Condition in a Subject
US9898656B2 (en) 2007-01-25 2018-02-20 Cyberonics, Inc. Systems and methods for identifying a contra-ictal condition in a subject
US9445730B2 (en) 2007-03-21 2016-09-20 Cyberonics, Inc. Implantable systems and methods for identifying a contra-ictal condition in a subject
US8036736B2 (en) 2007-03-21 2011-10-11 Neuro Vista Corporation Implantable systems and methods for identifying a contra-ictal condition in a subject
US8543199B2 (en) 2007-03-21 2013-09-24 Cyberonics, Inc. Implantable systems and methods for identifying a contra-ictal condition in a subject
US20080255582A1 (en) * 2007-04-11 2008-10-16 Harris John F Methods and Template Assembly for Implanting an Electrode Array in a Patient
US7974701B2 (en) 2007-04-27 2011-07-05 Cyberonics, Inc. Dosing limitation for an implantable medical device
US8306627B2 (en) 2007-04-27 2012-11-06 Cyberonics, Inc. Dosing limitation for an implantable medical device
US9788744B2 (en) 2007-07-27 2017-10-17 Cyberonics, Inc. Systems for monitoring brain activity and patient advisory device
US11406317B2 (en) 2007-12-28 2022-08-09 Livanova Usa, Inc. Method for detecting neurological and clinical manifestations of a seizure
US9259591B2 (en) 2007-12-28 2016-02-16 Cyberonics, Inc. Housing for an implantable medical device
US8260426B2 (en) 2008-01-25 2012-09-04 Cyberonics, Inc. Method, apparatus and system for bipolar charge utilization during stimulation by an implantable medical device
US9314633B2 (en) 2008-01-25 2016-04-19 Cyberonics, Inc. Contingent cardio-protection for epilepsy patients
US8204603B2 (en) 2008-04-25 2012-06-19 Cyberonics, Inc. Blocking exogenous action potentials by an implantable medical device
US20210045649A1 (en) * 2008-10-15 2021-02-18 Nuvasive, Inc. Neurophysiologic Monitoring System and Related Methods
US20200352468A1 (en) * 2008-10-15 2020-11-12 Nuvasive, Inc. Neurophysiologic Monitoring System and Related Methods
US8874218B2 (en) 2008-10-20 2014-10-28 Cyberonics, Inc. Neurostimulation with signal duration determined by a cardiac cycle
US8457747B2 (en) 2008-10-20 2013-06-04 Cyberonics, Inc. Neurostimulation with signal duration determined by a cardiac cycle
US8417344B2 (en) 2008-10-24 2013-04-09 Cyberonics, Inc. Dynamic cranial nerve stimulation based on brain state determination from cardiac data
US8768471B2 (en) 2008-10-24 2014-07-01 Cyberonics, Inc. Dynamic cranial nerve stimulation based on brain state determination from cardiac data
US8849409B2 (en) 2008-10-24 2014-09-30 Cyberonics, Inc. Dynamic cranial nerve stimulation based on brain state determination from cardiac data
US8849390B2 (en) 2008-12-29 2014-09-30 Cyberonics, Inc. Processing for multi-channel signals
US8588933B2 (en) 2009-01-09 2013-11-19 Cyberonics, Inc. Medical lead termination sleeve for implantable medical devices
US9289595B2 (en) 2009-01-09 2016-03-22 Cyberonics, Inc. Medical lead termination sleeve for implantable medical devices
US10653883B2 (en) 2009-01-23 2020-05-19 Livanova Usa, Inc. Implantable medical device for providing chronic condition therapy and acute condition therapy using vagus nerve stimulation
US8827912B2 (en) 2009-04-24 2014-09-09 Cyberonics, Inc. Methods and systems for detecting epileptic events using NNXX, optionally with nonlinear analysis parameters
US8239028B2 (en) 2009-04-24 2012-08-07 Cyberonics, Inc. Use of cardiac parameters in methods and systems for treating a chronic medical condition
US8786624B2 (en) 2009-06-02 2014-07-22 Cyberonics, Inc. Processing for multi-channel signals
US9643019B2 (en) 2010-02-12 2017-05-09 Cyberonics, Inc. Neurological monitoring and alerts
US9504833B2 (en) 2010-04-15 2016-11-29 Cardiac Pacemakers, Inc. Autonomic modulation using transient response with intermittent neural stimulation
US10668287B2 (en) 2010-04-15 2020-06-02 Cardiac Pacemakers, Inc. Neural stimulation with transient response between doses
US9126044B2 (en) 2010-04-15 2015-09-08 Cardiac Pacemakers, Inc. Autonomic modulation using transient response with intermittent neural stimulation
US9782591B2 (en) 2010-04-15 2017-10-10 Cardiac Pacemakers, Inc. Neural stimulation with transient response analysis between doses
US8562536B2 (en) 2010-04-29 2013-10-22 Flint Hills Scientific, Llc Algorithm for detecting a seizure from cardiac data
US8649871B2 (en) 2010-04-29 2014-02-11 Cyberonics, Inc. Validity test adaptive constraint modification for cardiac data used for detection of state changes
US8831732B2 (en) 2010-04-29 2014-09-09 Cyberonics, Inc. Method, apparatus and system for validating and quantifying cardiac beat data quality
US9700256B2 (en) 2010-04-29 2017-07-11 Cyberonics, Inc. Algorithm for detecting a seizure from cardiac data
US9241647B2 (en) 2010-04-29 2016-01-26 Cyberonics, Inc. Algorithm for detecting a seizure from cardiac data
US8679009B2 (en) 2010-06-15 2014-03-25 Flint Hills Scientific, Llc Systems approach to comorbidity assessment
US20130184781A1 (en) * 2010-07-06 2013-07-18 Emad N. Eskandar Brain Stimulation for Enhancement of Learning, Motivation, and Memory
US8641646B2 (en) 2010-07-30 2014-02-04 Cyberonics, Inc. Seizure detection using coordinate data
US9220910B2 (en) 2010-07-30 2015-12-29 Cyberonics, Inc. Seizure detection using coordinate data
US8948855B2 (en) 2010-09-16 2015-02-03 Flint Hills Scientific, Llc Detecting and validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex
US8452387B2 (en) 2010-09-16 2013-05-28 Flint Hills Scientific, Llc Detecting or validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex
US8571643B2 (en) 2010-09-16 2013-10-29 Flint Hills Scientific, Llc Detecting or validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex
US9020582B2 (en) 2010-09-16 2015-04-28 Flint Hills Scientific, Llc Detecting or validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex
US8852100B2 (en) 2010-10-01 2014-10-07 Flint Hills Scientific, Llc Detecting, quantifying, and/or classifying seizures using multimodal data
US8684921B2 (en) 2010-10-01 2014-04-01 Flint Hills Scientific Llc Detecting, assessing and managing epilepsy using a multi-variate, metric-based classification analysis
US8382667B2 (en) 2010-10-01 2013-02-26 Flint Hills Scientific, Llc Detecting, quantifying, and/or classifying seizures using multimodal data
US8888702B2 (en) 2010-10-01 2014-11-18 Flint Hills Scientific, Llc Detecting, quantifying, and/or classifying seizures using multimodal data
US8337404B2 (en) 2010-10-01 2012-12-25 Flint Hills Scientific, Llc Detecting, quantifying, and/or classifying seizures using multimodal data
US8945006B2 (en) 2010-10-01 2015-02-03 Flunt Hills Scientific, LLC Detecting, assessing and managing epilepsy using a multi-variate, metric-based classification analysis
US10285615B2 (en) 2011-01-20 2019-05-14 Widex A/S Personal EEG monitoring device with electrode validation
WO2012097872A1 (en) * 2011-01-20 2012-07-26 Widex A/S Personal eeg monitoring device with electrode validation
US9504390B2 (en) 2011-03-04 2016-11-29 Globalfoundries Inc. Detecting, assessing and managing a risk of death in epilepsy
US8562524B2 (en) 2011-03-04 2013-10-22 Flint Hills Scientific, Llc Detecting, assessing and managing a risk of death in epilepsy
US8562523B2 (en) 2011-03-04 2013-10-22 Flint Hills Scientific, Llc Detecting, assessing and managing extreme epileptic events
US8892207B2 (en) 2011-04-20 2014-11-18 Medtronic, Inc. Electrical therapy for facilitating inter-area brain synchronization
US8868173B2 (en) 2011-04-20 2014-10-21 Medtronic, Inc. Method and apparatus for assessing neural activation
US9173609B2 (en) 2011-04-20 2015-11-03 Medtronic, Inc. Brain condition monitoring based on co-activation of neural networks
US8914119B2 (en) 2011-04-20 2014-12-16 Medtronic, Inc. Electrical brain therapy parameter determination based on a bioelectrical resonance response
US8725239B2 (en) 2011-04-25 2014-05-13 Cyberonics, Inc. Identifying seizures using heart rate decrease
US9498162B2 (en) 2011-04-25 2016-11-22 Cyberonics, Inc. Identifying seizures using heart data from two or more windows
US8812098B2 (en) 2011-04-28 2014-08-19 Medtronic, Inc. Seizure probability metrics
US9402550B2 (en) 2011-04-29 2016-08-02 Cybertronics, Inc. Dynamic heart rate threshold for neurological event detection
US9878161B2 (en) 2011-04-29 2018-01-30 Medtronic, Inc. Entrainment of bioelectrical brain signals
US10206591B2 (en) 2011-10-14 2019-02-19 Flint Hills Scientific, Llc Seizure detection methods, apparatus, and systems using an autoregression algorithm
US20170083668A1 (en) * 2012-01-20 2017-03-23 International Business Machines Corporation Method and apparatus providing an online diagnostic assistant tool
US10448839B2 (en) 2012-04-23 2019-10-22 Livanova Usa, Inc. Methods, systems and apparatuses for detecting increased risk of sudden death
US11596314B2 (en) 2012-04-23 2023-03-07 Livanova Usa, Inc. Methods, systems and apparatuses for detecting increased risk of sudden death
US11103707B2 (en) 2013-01-22 2021-08-31 Livanova Usa, Inc. Methods and systems to diagnose depression
US10220211B2 (en) 2013-01-22 2019-03-05 Livanova Usa, Inc. Methods and systems to diagnose depression
US20140213926A1 (en) * 2013-01-25 2014-07-31 Medtronic, Inc. Notification indicative of a change in efficacy of therapy
US11890475B2 (en) 2013-01-25 2024-02-06 Medtronic, Inc. Notification indicative of a change in efficacy of therapy
US11207522B2 (en) * 2013-01-25 2021-12-28 Medtronic, Inc. Notification indicative of a change in efficacy of therapy
US9700723B2 (en) 2013-03-15 2017-07-11 Cyberonics, Inc. Optimization of cranial nerve stimulation to treat seizure disorders during sleep
US10080895B2 (en) 2013-03-15 2018-09-25 Cyberonics, Inc. Optimization of cranial nerve stimulation to treat seizure disorders during sleep
US9056195B2 (en) 2013-03-15 2015-06-16 Cyberonics, Inc. Optimization of cranial nerve stimulation to treat seizure disorderse during sleep
US9302109B2 (en) 2014-04-25 2016-04-05 Cyberonics, Inc. Cranial nerve stimulation to treat depression during sleep
US9585611B2 (en) 2014-04-25 2017-03-07 Cyberonics, Inc. Detecting seizures based on heartbeat data
US9918670B2 (en) 2014-04-25 2018-03-20 Cyberonics, Inc. Detecting seizures based on heartbeat data
US20170265764A1 (en) * 2014-11-24 2017-09-21 Ivan Osorio Subcortical (thalamic) automated seizure detection for contingent therapy delivery systems and methods
US10052489B2 (en) * 2015-03-23 2018-08-21 Greatbatch Ltd. Apparatus and method for implanting an implantable device
US20160279397A1 (en) * 2015-03-23 2016-09-29 Greatbatch Ltd. Apparatus and method for implanting an implantable device
US11065456B2 (en) 2015-03-23 2021-07-20 Greatbatch Ltd. Apparatus and method for implanting an implantable device
US11890483B2 (en) 2015-03-23 2024-02-06 Greatbatch Ltd. Apparatus and method for implanting an implantable device
US20160287127A1 (en) * 2015-04-06 2016-10-06 Forest Devices, Inc. Neuorological condition detection unit and method of using the same
US10456059B2 (en) * 2015-04-06 2019-10-29 Forest Devices, Inc. Neuorological condition detection unit and method of using the same
CN106390280A (en) * 2015-08-10 2017-02-15 华邦电子股份有限公司 Closed loop stimulating device and stimulating method thereof
CN109475295A (en) * 2016-06-29 2019-03-15 皇家飞利浦有限公司 Method and apparatus for health equipment and wearable/implantable devices
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11273283B2 (en) 2017-12-31 2022-03-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11318277B2 (en) 2017-12-31 2022-05-03 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
US11452839B2 (en) 2018-09-14 2022-09-27 Neuroenhancement Lab, LLC System and method of improving sleep
US11786736B2 (en) 2021-03-18 2023-10-17 Boston Scientific Neuromodulation Corporation Methods and systems for lead movement detection and response in DBS therapy
US11813458B2 (en) 2021-03-18 2023-11-14 Boston Scientific Neuromodulation Corporation Methods and systems for target localization and DBS therapy

Also Published As

Publication number Publication date
US8209018B2 (en) 2012-06-26
US20070213785A1 (en) 2007-09-13
WO2007106343A3 (en) 2007-11-01
WO2007106343A2 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
US8209018B2 (en) Probabilistic neurological disorder treatment
US9622675B2 (en) Communication error alerting in an epilepsy monitoring system
US9445730B2 (en) Implantable systems and methods for identifying a contra-ictal condition in a subject
EP2023809B1 (en) Method and system for loop recording with overlapping events
US7917199B2 (en) Patient event marking in combination with physiological signals
US9072832B2 (en) Clustering of recorded patient neurological activity to determine length of a neurological event
US8812098B2 (en) Seizure probability metrics
US7715919B2 (en) Control of treatment therapy during start-up and during operation of a medical device system
US7282030B2 (en) Timed delay for redelivery of treatment therapy for a medical device system
US7676263B2 (en) Minimally invasive system for selecting patient-specific therapy parameters
US9326720B2 (en) Wireless, implantable electro-encephalography system
US7917206B2 (en) Signal quality monitoring and control for a medical device system
US8768446B2 (en) Clustering with combined physiological signals
WO2007126597A2 (en) Flexible memory management scheme for loop recording in an implantable device
US20220401739A1 (en) Cloud-based sensor operation adapted to patient behavior
US20220400952A1 (en) Cloud-based patient monitoring and pain management system
KR102368615B1 (en) Feedback stimulation system based on micturition diary and control mehtod thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: MEDTRONIC, INC., MINNESOTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:OSORIO, IVAN;REEL/FRAME:019478/0924

Effective date: 20070608

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION